[{"article": "\u201cThere\u2019s some danger of kids getting a rash, and it would be inadvisable to give it to women in the early stages of pregnancy,\u201d he said.\n\u201cBut here every one of those things fails.\u201d One of Dr. Barrett\u2019s papers on echinacea was included in the analysis.\n\u201cThese results have pushed me toward the idea.\nSome might not have a large enough sample to find a small but statistically significant effect.\nThe authors acknowledged certain weaknesses in their study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter does an excellent job describing the rigor of the study and getting the author, an interested party, and a disinterested party to provide perspective. ", "answer": 1}, {"article": "By contrast, the lifetime risk of breast cancer among women generally is about 12 percent, and for ovarian cancer, it's less than 2 percent.\n\"These findings really emphasize how important it is for all women with a family history of early breast or ovarian cancer to undergo genetic testing,\" said Dr. Virginia Kaklamani, co-author of an editorial that accompanied the study.\nHowever, \"what our findings show is that women who choose to have these surgeries will reduce their risk of dying of breast or ovarian cancer by about 70 to 80 percent, which is pretty profound,\" said study senior author Dr. Timothy Rebbeck, a professor of epidemiology at the University of Pennsylvania School of Medicine.\nKaklamani added that she hoped the findings would encourage more women to ask their primary care physicians whether they are candidates for genetic counseling.\nThe findings are published in the Sept. 1 issue of the Journal of the American Medical Association.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story includes comments from an author of an editorial in the journal who was not involved in this study. Although the story does not report financial or other information about the sources, the study was funded by a variety of grants from public agencies and foundations and neither the researchers nor the editorial writers reported any relevant financial disclosures.", "answer": 1}, {"article": "\u201cThe beauty of the procedure is that it is a nonsurgical procedure,\u201d Chattoo said.\nDr. Prem Chattoo, a New York based gastroenterologist, told FoxNews.com that the balloon is placed it into the stomach through the mouth.\nChattoo said that even if the balloon were to pop, the saline would be absorbed and pose no harm to the patient.\nNow, there is a new solution for people with a body mass index (BMI) between 30 and 40 that want to lose weight called the Orbera gastric balloon.\nIn addition to eliminating the scarring and risks involved with more invasive options, Chattoo said that the recovery time is also much faster.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites two sources. One is a pleased former patient who used Orbera. The other is a doctor who provides Orbera to his clients. There are no outside sources who can an offer impartial assessment of Orbera: it\u2019s effectiveness, safety or novelty. And the story does not tell readers that the doctor offers Orbera to his clients (though a critical news consumer would probably guess). We only know because we went to his website (which the story links to).", "answer": 0}, {"article": "Hot flashes, which mostly affect women transitioning to menopause and already in that phase of life, involve a sudden sensation of heat, sometimes accompanied by sweating or visible reddening of the skin.\nFreedman said that the overall research on antidepressants and hot flashes is still inconsistent.\n\u201cBut my feeling is that it\u2019s the placebo effect,\u201d Freedman said, referring to the phenomenon of study participants on placebos improving because they believe they are getting a real treatment.\nIn general, studies of hot-flash remedies over the years have \u201cvirtually always found a large placebo effect,\u201d Freedman noted in an interview.\nIn fact, Freedman said, there\u2019s some evidence that lowering serotonin levels does not worsen hot flashes \u2014 which would be expected if the \u201cserotonin theory\u201d is correct.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article does appear to use independent sources including interviewing Dr Robert Freedman, a psychiatrist who was skeptical of the true benefits of using antidepressants to treat hot flashes.", "answer": 1}, {"article": "GHRH, a hormone produced by the hypothalamus in the brain, is linked to the insulin system, but also has a host of other effects.\nAn expert who wasn\u2019t involved in the research echoed the cautions.\nThe new study, published Monday in the Archives of Neurology, included 152 people aged 55 to 87.\n\u201cOur work and others\u2019 has shown that exercise really does make a difference.\u201d\n\u201cOn self-report, many of the folks in the active group reported they felt better,\u201d Baker, who led the study, told Reuters Health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A key independent expert was quoted.", "answer": 1}, {"article": "Fibromyalgia is a syndrome marked by widespread pain \u2014 including discomfort at specific \u201ctender points\u201d in the body \u2014 along with symptoms such as fatigue, irritable bowel and sleep problems.\nAnother difference is that, right now, only a small number of healthcare providers practice affective self-awareness, according to Schubiner.\nPart of that, according to the researchers on the new study, may be because standard treatments do not specifically address the role psychological stress and emotions can play in triggering people\u2019s pain.\nSchubiner also acknowledged that this general \u201cmodel\u201d for understanding and addressing fibromyalgia pain is controversial.\nA key difference, Schubiner said, is that affective self-awareness asks people to \u201cdirectly engage\u201d the emotions that may be helping to drive their symptoms.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included only one expert source, Dr. Howard Schubiner, who in addition to being\u00a0an author on the paper\u00a0is also the original developer of affective self-awareness therapy. While these credentials no doubt make him an authority on the treatment and an important\u00a0interview subject, they\u00a0also create the appearance that he\u00a0could be biased in\u00a0favor of the approach. Another expert perspective would have been useful, for example, to explain why some professionals disagree with Schubiner\u2019s approach to fibromyalgia treatment. Schubiner suggests that\u00a0his ideas are \"controversial,\" but we never\u00a0learn what it is that other experts in the field object to. \u00a0", "answer": 0}, {"article": "Men and women with mildly high blood pressure who ate three kiwi fruits a day for eight weeks had systolic blood pressure levels that were 3.6 millimeters of mercury lower than those of volunteers who ate an apple a day.\nDr. Suzanne Steinbaum, a preventive cardiologist with Lenox Hill Hospital in New York City, agreed.\nDon't start popping lutein in supplement form based on these results, he noted.\nDr. Elliott M. Antman, a professor of medicine at Harvard Medical School in Boston, said that while promising, the new study is small.\nThey changed nothing in their diet other than adding the fruit.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several independent sources were quoted.", "answer": 1}, {"article": "While skeptics may question the idea of using psychedelics as treatment for psychological distress, Hendricks emphasizes that he does not advocate for rampant recreational use of psychedelics, or widespread legalization.\nThe UAB isn't the first study to flirt with this idea.\nPerhaps this study will be a turning point in how our culture regards psychedelics and mental health.\nIt turns out contemporary science may back these ancient claims.\n\"But I'm excited and hopeful.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article\u2019s sole source is the lead author of the study. Especially for a controversial topic such as this one, we think it\u2019s important to include feedback from experts with differing perspectives.", "answer": 0}, {"article": "American Congress of Obstetricians and Gynecologists (ACOG) guidelines call for all women of child-bearing age - not just those who plan to get pregnant - to take 400 micrograms of folic acid daily to prevent birth defects.\nBut some experts aren't quite ready to tout the benefits of folic acid too loudly, particularly for autism prevention.\n\"It actually supports the idea of actionable things women can do before they become pregnant, and right as conception happens.\"\nThe Norwegian study is the largest to date on the benefits of folic acid for autism prevention, and marks one of the first tangible things a woman can do to reduce her risk of giving birth to a child with the disorder.\n\"The reality is, autism is a complex disorder and our best answers about causes and treatment are going to be complex as well.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes a nice mix of voices, including experts from an autism advocacy group, the March of Dimes, and in independent autism research program. This was a strong point of the story.", "answer": 1}, {"article": "These showed progression-free survival was 4.2 months with Opdivo and 5.9 months with chemotherapy, although the difference was not statistically significant.\nMany experts have been skeptical about this approach and investors\u2019 expectations, up until now, have been quite low.\nThe various findings suggest that treating lung cancer - the biggest cancer killer globally - with powerful new immune system-boosting medicines is going to involve more permutations than some experts originally expected.\nMerck had already said in June that Keytruda worked in the trial but the scale of the benefit was only disclosed at ESMO.\nThey are expected to sell tens of billions of dollars in the years ahead, with lung cancer the largest market.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story just barely scores a Satisfactory rating on this one. It is clear that Merck & Co. is funding this research. A couple of sources are overtly linked to the company. A third, Dr. Stefan Zimmerman, appears to be independent, though he\u00a0wasn\u2019t quoted saying anything that helped illuminate the findings, instead he\u2019s quoted as saying \u201cRemember this day. It\u2019s a new day for lung cancer treatment.\u201d Some additional commentary from an oncologist or a patient advocate would likely have helped put the findings in perspective.", "answer": 1}, {"article": "An experimental Johnson & Johnson drug substantially reduced the severity of the inflammatory skin disorder psoriasis, according to a new study.\n\nJ&J is developing ustekinumab as part of a new category of drugs that targets proteins known as interleukins. In addition to psoriasis, J&J is studying the compound's potential to treat Crohn's disease, a gastrointestinal ailment.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only non-peer-reviewed company-sponsored research was reported.\u00a0 No independent sources were cited. ", "answer": 0}, {"article": "Some cold sufferers have been wary about using zinc since the Food and Drug Administration warned consumers to stop using Zicam nasal sprays and swabs, which contain zinc, after numerous reports that some users lost their sense of smell after using the product.\nTwo of Dr. Prasad\u2019s studies were included in the Cochrane report.\nWhile the findings are certain to send droves of miserable cold sufferers to the drugstore in search of zinc treatments, the study authors offered no guidance on what type of zinc product to buy.\nEven so, the new report gives credence to the long-debated theory that zinc can be an effective treatment for colds.\nThe studies were all considered to have good methodological quality with a low risk of bias, but they were far from perfect.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes commentary from the review\u2019s lead author, as well as Dr. Prasad, \u201can early pioneer of research into zinc as an essential mineral.\u201d Two of Dr. Prasad\u2019s many articles were included in the Cochrane Review. Quotes from an independent expert would have been welcomed.\n", "answer": 0}, {"article": "About 35 million Americans have migraines, according to the American Headache Society, and about 20% to 30% of these patients have headaches that are preceded by visual or other sensory warning signs.\nCompared to patients who got sham treatments, more patients treated with the experimental device, known as single-pulse transcranial magnetic stimulation (sTMS), were pain-free two hours later.\nDrugs commonly used in the treatment of severe headaches are generally not considered effective in the aura phase of migraine attacks, and many patients want to treat their migraines without using drugs, neurologist and headache specialist Richard B. Lipton, MD, tells WebMD.\nMarch 3, 2010 -- A handheld device that magnetically zaps pain may be a promising new treatment for patients with a common type of migraine.\n\"Some people don't tolerate the drug treatments very well and others just want to avoid them.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story did at least include comments from the editorial writer who injected some cautionary notes into the discussion. And it did point out the conflicts of interest associated with the trial. This study was funded by Neurolieve, the company that makes the device used in the trial. Furthermore, the lead author of the study owns stock in this company.\u00a0\u00a0 ", "answer": 1}, {"article": "Among its raft of recommendations, the consensus statement says that:\n\u2022 Should aim to play for 150 minutes/week, or do less, but couple golf with other physical activity, and walk the course rather than ride a golf cart\n\u2022 Do warm-up/strengthening exercises to cut the risk of injury and use sun-cream and wear collared shirts/blouses to minimise the risk of skin cancer\n\u2022 Build on existing initiatives to promote inclusivity and develop environments and price structures that will be attractive to everyone\n\u2022 Develop a culture that will inspire more women and girls to play golf\n\u2022 Make every effort to promote equality and diversity, and boost accessibility\n\u2022 Promote sustainability through wildlife conservation and by restricting the use of water, energy, and pesticides\n\u2022 Provide additional facilities at clubs, such as a gym, walking routes, cr\u00e8ches and improve the focus on health and safety, with the provision of healthy foods, defibrillators, and speed limiters on golf carts, for example\n\u2022 Promote the benefits of regular physical activity, including golf, for people of all ages, genders, and income brackets\n\u2022 Work with industry and national associations to boost take up of the sport, particularly in groups where physical activity levels are low\n\u2022 Work with industry and regulatory bodies to get golf included in the Paralympics\n\n\"These outputs, if widely shared and adopted, will contribute to an improved understanding of golf and health, and aid these groups in making evidence-informed decisions and to improve health and wellbeing,\" the consensus statement concludes.\nMore people might be keen to take it up if golf were promoted as an enjoyable, lifelong outdoors activity that affords a sense of community and competitive challenge while providing some 'me time' as well as helping to fulfil recommended exercise quotas, says the statement.\nIt can provide moderate intensity aerobic physical activity, and its health benefits are greatest for players (and spectators) who walk round the course rather than opt for a golf cart.\nThese set out what is currently known about golf's associations with health; the factors that may help or hinder take-up of the sport; and a series of recommendations for golfers, industry leaders, and policy makers on how best to maximise its health benefits, promote sustainability, and widen participation.\nThis can put people off, says the statement.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "This is the second major weakness of this news release.\nIt\u2019s not mentioned that this \u201c2018 Consensus Statement on Golf and Health\u201d was funded by an unrestricted grant from the World Golf Foundation.\nTwo of the authors receive fees from the European Golf tour and one is the director of Golf Development at the Royal and Ancient Golf Club in St. Andrews, Scotland.", "answer": 0}, {"article": "In addition, Drs.\nOur next step is getting approval from the FDA.\u201d\n\nNote: This work was supported by the Coulter Foundation, V Foundation, National Science Foundation, and Bill and Melinda Gates Foundation.\nThe pump is reusable; the balloon, microchip, and lab test together cost around $20, all supporting the increasing acceptance of breath tests as a cost-effective, easy-to-perform, non-invasive, and rapid option for the diagnosis of lung cancer.\nNewswise \u2014 Chicago \u2014 A single breath may be all it takes to identify the return of lung cancer after surgery, according to a study posted online today by The Annals of Thoracic Surgery.\nNow the test is being used to monitor for disease recurrence.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release earns a satisfactory here for providing both funding sources and pointing out that three of the seven researchers have ties to a medical equipment company which deals with breath analysis. The information, however, lies at the end of the story in a portion commonly referred to as \u201cboilerplate\u201d information, which readers often ignore. Incorporating such info into the body of the release better serves readers.", "answer": 1}, {"article": "At Cooper, cardiologist Phillip Koren said he and colleagues have used the Lariat on the left atrial appendage of about 10 patients in the last six months. The closure was unsuccessful in a few of those cases, but in those, there have been no strokes, said Koren, deputy director of the Cooper Heart Institute. None of the 10 patients suffered adverse events from the device.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quoted sources beyond only the study authors. Some of the study authors disclosed relationships with medical device companies such as Boston Scientific (which makes the Watchman device mentioned in the story); however, a quick search did not reveal any conflicts of interest for Drs. Giri \u00a0and Koren, the two expert sources who are directly quoted by the story.", "answer": 1}, {"article": "Older adults with mild cognitive impairment have less severe memory loss than those with Alzheimer's but often go on to develop the disease.\nBut fish and chips lovers, take note: No cranial benefit was evident with respect to consumption of fried fish.\n\"And that would be a very small lifestyle change that can affect disease risk a long time down the line.\"\nFor now, the connection must be viewed as an association, rather than a cause-and-effect.\n\"One has to wonder if there are other factors associated with fish consumption that they didn't measure that might be protective,\" he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "At least the story had one independent source, a NY neurologist who said, \u201cOne has to wonder if there are other factors\u2026 that they didn\u2019t measure.\u201d\u00a0 But his comments were buried deep in the story, as was the line \u201cFor now, the connection must be viewed as an association, rather than a cause-and-effect.\u201d\u00a0 That should have been in the second paragraph at the latest.\n ", "answer": 1}, {"article": "Some prostate cancers evolve to use energy from lipids (fat).\n\u201cThis finding may have a huge impact on patients with CRPC that had very few options before,\u201d says Schlaepfer.\nIn fact, we are already able to block the action of the CPT1A enzyme.\n\u201cThis is a huge development for men with CRPC that previously did not have many options,\u201d says Isabel Schlaepfer, PhD, CU Cancer Center member, assistant professor in the Division of Medical Oncology and senior author of the study.\n\u201cWe had to find a way to block this pathway so that the cancer would not be able to burn lipid in the mitochondria to acquire energy to resist therapy,\u201d explains Schlaepfer.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funders aren\u2019t named in the news release. There is no information suggesting\u00a0that the researchers are connected to the companies that make the drugs in question or are otherwise invested in this particular treatment paradigm, but it would have been nice to be informed if this was or was not the case.", "answer": 0}, {"article": "\"We believe the people who do go home have fewer neurological problems that impair the quality of life,\" Dr. Callaway said.\nBut putting the therapy into practice in many hospitals has been slow.\nBut that number is one or two higher than would occur without hypothermic therapy.\nFor now, Dr. Callaway said, there's an upswing in hospitals using the therapy and in two years it will be more routine.\nThat's most likely what happened to Mr. Beck, whose heart arteries were clear.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While quotes from several physicans were included in this story as well as quotes from a patient who had had the treatment, the sources of the background information about the treatment and the studies about its benefit were not mentioned. So readers get the perspectives of \"believers\" minus any hard evidence.\u00a0 ", "answer": 0}, {"article": "Methods such as cognitive behavioral therapy, in which psychiatrists help patients overcome destructive behaviors and thought patterns, and interpersonal therapy, which focuses more on the effect depression has on relationships, seem to be equally effective in treating depression, particularly in adolescents.\nA comment attached to the Oxford paper, written by Dr. Jon Jureidini, a child psychiatrist at the Women\u2019s and Children\u2019s Hospital in Adelaide, Australia, goes even further in decrying the use of antidepressants in kids.\nThe only drug to pass the test was fluoxetine, sold in the U.S. under the trade name Prozac.\nThat\u2019s because the FDA has deemed that Prozac has demonstrated benefits that outweigh one of the suspected downsides of antidepressants in kids and teens: disrupting brain development.\nDr. Andrea Cipriani, psychiatrist and lead author on the study, says these are concerns that practicing psychiatrists confront daily.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not mention that the study was funded by the Chinese government through the National Basic Research Program of China or that the researchers collectively have financial ties to numerous drug companies.", "answer": 0}, {"article": "\"It's premature to make any conclusions,\" he said.\nBut Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston, said that this study was too small to reach any definitive conclusion about the value of vitamin D in fighting prostate cancer.\nMONDAY, March 23, 2015 (HealthDay News) -- Vitamin D supplements may slow or prevent low-grade prostate cancer from progressing, a small new study suggests.\n\"Vitamin D decreases inflammation in tissues, and inflammation is a driver of cancer,\" explained Bruce Hollis, the study's lead researcher and a professor of pediatrics, biochemistry and molecular biology at the Medical University of South Carolina in Charleston.\nHowever, the study was small, and results from a larger trial aren't expected for several years, he added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article quotes the chief of radiation oncology at Brigham and Women\u2019s Hospital in Boston in the strongest possible way concluding that the study was too small to establish any value of vitamin D supplements and prostate cancer prevention or therapy. There is no indication that the vitamin supplement industry had any role in the research. However, the article might have pointed out that the researcher, Bruce Hollis, has been conducting studies about the benefits of vitamin D for decades and is a widely quoted expert on the potential benefits of the vitamin in disease prevention. Hollis was quoted elsewhere on this study saying that \u201cdoctors should be recommending vitamin D\u2083 for men with low-grade prostate cancer,\u201d and we\u2019re glad to see that HealthDay did not pass along those overly enthusiastic comments.", "answer": 1}, {"article": "Investigators evaluated the effect of the USPSTF guideline on the number and distribution of new prostate cancer diagnoses in the U.S.\nThe study showed that 12 months after the draft guidelines were published diagnoses of new low risk cancers had fallen by 37.9%, and continued to fall more rapidly than other disease risk strata, suggesting that, in this regard, the USPSTF recommendation had its intended effect,.\n\"Future research should focus on prostate cancer screening paradigms that both minimize harms and maximize the potential benefits of screening, as well as accounting for individual patient risk factors and preferences.\"\nThe uncertain benefit of PSA based screening, combined with the complications associated with treatment, led the USPSTF to conclude in October 2011 that the harms of PSA based screening outweighed the benefits, leading it to recommend against regular screening.\n\"While some of the effects of this guideline may be beneficial in terms of reducing harms of over diagnosis and overtreatment, the reduction in intermediate and high risk cancer diagnoses raises concern for delayed diagnoses of important cancers associated with inferior cancer outcomes,\" noted Dr. Barocas.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not discuss funding for the study and does not disclose the fact that some authors have financial relationships with companies that make prostate cancer tests and treatments.", "answer": 0}, {"article": "Aneurysms are weakening, or bulging, of blood vessels that can rupture and become life-threatening.\n\u201cPrior to gaining approval from the Food and Drug Administration, patients with many types of aneurysms and aortic conditions had limited treatment options,\u201d said Azizzadeh, director of Vascular Surgery at the Smidt Heart Institute at Cedars-Sinai.\nAfter my recovery, I know I will feel stronger and healthier, and will remain forever grateful.\u201d\n\nSince Angelino\u2019s surgery, Azizzadeh who, in conjunction with medical device company Medtronic, served as the national principal investigator in clinical tests of the device \u2013 has performed several additional, successful surgeries.\nNewswise \u2014 LOS ANGELES (Dec. 5, 2018) - Vascular surgeon Ali Azizzadeh, MD, was the first to use a newly approved, minimally invasive device to perform a series of innovative surgeries on patients with aneurysms of the aorta, the main vessel that delivers blood from the heart to the rest of the body.\nCompared to other technologies, the stent graft can travel through smaller, curvy vessels and better adjust to a patient\u2019s anatomy.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funders of the study are not named (nor is the study that led to the device approval identified or linked). It is good to know that the surgeon featured in the news release, Dr. Azizzadeh, works \u201cin conjunction with medical device company Medtronic, [and] served as the national principal investigator in clinical tests of the device.\u201d", "answer": 0}, {"article": "The Centers for Disease Control and Prevention estimates there are 300,000 sports concussions among children each year.\n\u2026 It's like a sophisticated video game, but the numbers that are generated from the report are critical in helping to better identify the severity and recovery from the injury.\"\nBut, Regan adds, diagnosing them can be daunting: While there are some physical symptoms such as headaches, nausea, dizziness and blurred vision, concussions don't cause bleeding or swelling in the brain and don't show up on X-rays.\nBut for students such as Aldrich, who don't know their baseline, extra caution is the doctor's order.\nHe wants her to avoid exerting herself, physically and mentally, because a \"bump on the head\" is a lot more dangerous than it sounds.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\nThe broadcast includes interviews with an independent expert who describes the potential problems posed by premature return to play. However, it fails to mention that the other expert interviewed, Michael Collins, PhD, is a part owner in the company that developed and licenses the Impact system.\n", "answer": 0}, {"article": "RA Nash et al.\nThe trial, called HALT-MS, was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and conducted by the NIAID-funded Immune Tolerance Network (ITN).\nThe researchers published three-year results from the study in December 2014, and the final five-year results appear online Feb. 1 in Neurology, the medical journal of the American Academy of Neurology.\nThis work was sponsored by NIAID, NIH, and conducted by the ITN under award number AI109565 and NIAID-funded statistical and clinical coordinating centers under award number AI117870.\nThree participants died during the study; none of the deaths were related to the study treatment.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that the research was sponsored by the National Institute of Allergy and Infections Diseases and the NIH. But it does not mention that Baxter Healthcare Corp. supplied equipment for the trial or that several study authors have financial relationships with biotechnology companies, which are listed in the study.\nIt\u2019s not easy to determine which companies have financial interests in hematopoietic stem cell transplantation, but Baxter has at least one patent relating to the procedure. This makes full disclosure an important aspect of the reporting of this trial. ", "answer": 0}, {"article": "Suvorexant is part of a class of drugs called Dual Orexin Receptor Antagonists or DORAs, which work by blocking chemical messengers called orexins.\nEmmanuel Mignot of Stanford University, who wrote a commentary on the study in the same journal, said the findings show promise.\nSo far, Merck has not seen any cases of narcolepsy, a sleep disorder marked by daytime sleepiness, in its late-stage clinical trials, Renger said.\nExperiments in animals suggest Merck\u2019s sleep drug Suvorexant, now before the U.S. Food and Drug Administration, may avoid these side effects, the company said.\nOrexins originate in a specific region of the hypothalamus, so targeting them may have less impact on other brain functions, Renger said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does report that the researchers work for Merck, the company applying for approval to sell a similar drug. The story would have been better if it had included comments from an interview with an independent source (as did the HealthDay story we also reviewed), rather than just an excerpt of a journal commentary article.", "answer": 1}, {"article": "MRI highlights angiogenesis, the formation of new blood vessels, especially those that feed cancerous tissues.\nMONDAY, Nov. 29, 2010 (HealthDay News) -- Women who have had breast cancer should consider annual screening with breast MRI in addition to an annual mammogram, new research indicates.\nHowever, still more research is needed to clarify the role of MRI in this population, she said.\nOf these, 327 had a genetic or family history; 646 had a personal history of breast cancer that had been treated.\nWhile the society recommends neither for nor against MRI imaging for those with a personal history of breast cancer, he said it regularly reviews study findings to determine if the guidelines need updating.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThis story does include an independent source. However, it fails to report that the senior researcher involved with this study disclosed that she is a consultant to a manufacturer of MRI scanners and that another researcher has received grant support from the MRI scanner company.\nReference:\nMeeting abstract disclosures \nhttp://rsna2010.rsna.org/program/event_display.cfm?em_id=9006996", "answer": 0}, {"article": "The studies suggest that fewer physicians are recommending annual mammograms for women in their 40s, fewer patients in that age group are getting screened and that tumors found through routine mammography are more likely to be detected in early stages of cancer.\nThe studies examined the impact of the controversial guidelines issued by the U.S. Preventive Services Task Force, a federal advisory board.\nBreast cancer ID'd more accurately by docs who see more scans\n\nPlecha's findings were not surprising to Moyer.\nThese cancers were more treatable because they were caught in earlier stages, Plecha said.\nThe task force did not say don't get mammograms, Moyer said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Good sourcing, including \u2013 unlike the competing Denver Post story \u2013 input from the chair of the US Preventive Services Task Force.", "answer": 1}, {"article": "When they accounted for whether or not men were overweight and their other health problems and medications, it turned out that those with fatal cancers were 63 percent less likely to have ever taken a statin, according to findings published in Cancer.\nBut they jibe with previous studies suggesting that getting cholesterol levels under control might help reduce the risk of life-threatening disease, researchers said.\nThe findings don\u2019t prove that the drugs, called statins, ward off aggressive cancer.\nMarcella\u2019s team didn\u2019t have the data to figure out if taking a statin for longer, or starting one earlier, was more beneficial than more limited use of the drugs.\nClose to one in four of the men in both groups combined had ever taken a statin.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Important perspective added by independent expert from Duke who was not involved in the study.", "answer": 1}, {"article": "Floaters become more common with age, and although some people simply get used to them, others are bothered by them or their vision is impaired.\nA limitation of the study was its small size and short follow-up period, the researchers said.\nFor her part, Goldberg said that although \"there was significant improvement in patients' symptoms following treatment, and no significant complication was seen,\" these findings are early and \"it is difficult to predict the long-term safety of this laser procedure.\"\nHowever, Shah and Heier said there are few published studies on the laser treatment's effectiveness in treating floaters.\nThey explained that, currently, there are three management options for floaters: patient education and observation; surgery; and a laser procedure known as YAG vitreolysis.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does quote an independent source in the story, rather than relying on the study\u2019s authors.\u00a0 It does not, however, provide any information relating to possible conflicts of interest. For example, the study was funded by a large ophthalmology clinic where this procedure is presumably performed \u2014 and which might stand to gain more business if it\u2019s proven to work effectively.", "answer": 0}, {"article": "\u201cI\u2019m very hesitant to use ceramic-on-ceramic now,\u201d Dr. Orozco said, \u201cunless we are talking about somebody very young.\u201d\nBut Dr. Fabio Orozco, a surgeon at the Rothman Institute, a major orthopedics group in Philadelphia, said that a recently completed review of about 1,500 Rothman patients with ceramic hips had found that the squeaking condition occurred in 49 of them, or about 3 percent.\nWhatever the actual frequency, some investigators who have looked at the problem say the squeaking seems to be associated with extreme flexing of the ceramic implants, but exactly how is unclear.\n\u201cPublished research shows squeaking is rare compared with other total-hip-related risks like infection, dislocation and leaving patients with uneven leg length.\u201d\n\nBut plaintiffs lawyers, who have already filed scores of lawsuits on behalf of ceramic hip patients, are gearing up to argue that squeaking is not a minor problem for many who experience it.\nDr. Bried, who implanted Mr. Mueller\u2019s hip last year, said he was concerned that squeaking might be \u201ca harbinger of something similar.\u201d\n\nMr. Mueller said Dr. Bried had told him to consider getting the hip replaced \u201csooner rather than later.\u201d\n\nStryker says such fears are overblown.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites 4 patients, 4 surgeons, a spokesperson for implant maker Stryker, and a lawyer representing aggrieved patients. All in all, they provide a balance of viewpoints. The story mentions a conflict of interest for one surgeon. It appears that 2 of the patients are clients of the lawyer.", "answer": 1}, {"article": "ORMD-0801 goes from the gut to the liver, while injected insulin circulates throughout the body before it gets there.\nBut the data from the Phase II, 180-patient trial represents a major milestone.\nOramed said it plans to publish more detailed data from the study once it has had time to analyze the full results.\nA safe and effective oral insulin, if approved, is expected to become a multibillion-dollar product.\nThe positive results must be replicated in a larger Phase III trial before the drug, known as ORMD-0801, can be submitted for approval.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes comments from the CEO.\u00a0Getting an independent voice is especially important when the data is preliminary and comes from the pharmaceutical company.", "answer": 0}, {"article": "The American Orthopaedic Society for Sports Medicine (AOSSM) is the premier global, sports medicine organization representing the interests of orthopaedic surgeons and other professionals who provide comprehensive health services for the care of athletes and active people of all ages and levels.\n\"Our findings note that patients older than 40 may benefit from using a fresh osteochondral allograft transplantation to treat focal cartilage defects, a common cause of knee pain in adults,\" said lead author, Dennis Crawford, MD, PhD from the Oregon Health and Science University in Portland, Oregon.\nA statistically significant improvement for both groups was noted for the final follow-up for IKDC and all five KOOS sub-scores.\n\"This type of osteochondral allograft transplantation has traditionally been used in younger active patients with cartilage disorders.\nWe cultivate evidence-based knowledge, provide extensive educational programming, and promote emerging research that advances the science and practice of sports medicine.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not say how the research was funded, nor does it address conflicts of interest. To be clear, the research may have been internally funded, and there may well be no conflicts of interest \u2014 but it\u2019s important for a release to state that explicitly.", "answer": 0}, {"article": "Air is suctioned through the side channels to emulate breathing.\nThe institute\u2019s goal is to create 10 different organ systems that can be joined together by blood vessel channels to simulate human physiology on a microscale and provide a cheaper, more reliable way to test new drugs.\nMore often than not, these studies produce mixed data that don\u2019t tell researchers much about whether it is safe and effective for humans.\nResearchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University have developed a beautiful solution: Organs-On-Chips.\nIngber says some scientists are interested in using the chips to conduct research that would be unethical if performed on people, such as studying the effects of gamma radiation on the human body.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This was a two-source story, but both quoted researchers are leading organ-on-chip projects and so have a clear stake in this technology. One researcher created the organ-on-chip and is part of a team seeking to commercialize the technology. The other, though based at NIH, would seem to have a strong professional interest in seeing the technology succeed. The report needed an independent source, who could talk more thoroughly about the limitations of this technology and whether the expectations put forth by the article are realistic. For example, the story could have asked the head of research for a major drug company about their views on such new technologies, and whether they had any immediate plans to replace existing systems with this new one.", "answer": 0}, {"article": "In a separate study presented at ASCO, previously untreated people with advanced melanoma treated with Bristol-Myers Squibb\u2019s Yervoy, or ipilimumab, plus chemotherapy lived an average of two months longer than people who got chemotherapy alone.\nMeanwhile, doctors are already working out treatment strategies.\nShe and others expect vemurafenib to be approved this year.\n\u201cThis is really unprecedented time to have two new approaches to treat advanced melanoma,\u201d said Dr. Lynn Schuchter of the University of Pennsylvania in Philadelphia, a melanoma expert who moderated a panel discussion of the drugs.\nAbout 18 percent of patients developed a low-grade skin cancer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent source \u2013 a panel moderator \u2013 and a stock analyst were quoted.", "answer": 1}, {"article": "In a twist in the debate about the safety of menopause hormones, new research suggests the real problem may not be the hormone itself, but the fact that it's typically swallowed as a pill.\n\nThis week, the medical journal Circulation offers some of the strongest evidence yet that the risks of hormones are dramatically reduced when the drugs are absorbed through the skin in patches and gels rather than taken as pills. The study by French researchers showed that one of the most serious risks associated with hormone use -- blood...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes several independent experts who have differing views on the value of the new information. It did an especially good job of noting conflicts of interest where they existed. ", "answer": 1}, {"article": "In the six studies that looked at decaf coffee, the researchers found, people who consumed more than three or four cups a day were at 36 percent lower risk of diabetes.\nIt\u2019s also not possible to say from the current evidence that heavy coffee drinkers (and tea and decaf drinkers) don\u2019t have other characteristics that might protect them against developing diabetes, they add, such as eating a healthier diet.\nThe current analysis could have overestimated the effect of these beverages on diabetes risk due to statistical issues with the smaller studies, Huxley and her colleagues note.\nIn the years since then, they add, the amount of research on coffee and diabetes risk \u201chas more than doubled,\u201d while other studies have suggested that tea and decaf coffee may also be preventive.\nTo update the evidence, Huxley and her team analyzed 18 studies on coffee, decaf, and tea and the risk of type 2 diabetes published between 1966 and 2009, including just shy of 458,000 people in all.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\u00a0No independent sources were quoted in the story.\u00a0 We especially feel that this was warranted given the inclusion of the researcher\u2019s bold claims of potential impact\u00a0 of the findings. ", "answer": 0}, {"article": "The American Cancer Society has more on lymphoma.\nThe study was presented Monday at the annual meeting of the American Society of Hematology in Atlanta.\nPeople whose physical activity was greater than normal before diagnosis were less likely to have died from lymphoma, or from any other cause, than were those who'd been less active, the study found.\nThrough periodic questionnaires, the researchers tracked the participants' physical activity levels from before their cancer diagnoses until three years afterwards.\nResearch presented at meetings should be considered preliminary because it has not been subjected to the rigorous scrutiny given to research published in medical journals.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources are cited in the story, nor does the story tell readers who funded the relevant study or whether there are any potential conflicts of interest among the researchers. (The study abstract itself doesn\u2019t tell readers who funded the study, though it does list the various industry relationships of the researchers.)", "answer": 0}, {"article": "\"When parents have a child diagnosed with an autism spectrum disorder, one of the first questions they often ask is 'how did this happen?'\nStill, there is much geneticists can't tell parents.\n\"CMA should be added to first-tier genetic testing for autism spectrum disorders.\"\nBut that leaves 85 percent or more families with little explanation for the disorder, Marion said.\nStandard practice is to offer children with autism two tests as a first-line genetic work-up: karyotype and fragile X testing, the researchers said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story included perspective from a pediatric geneticist unaffiliated with the research. ", "answer": 1}, {"article": "\"The issue is, can you detect these in patients that don't have advanced cancer?\" Venook said. \"The answer is, we don't know.\" The numbers tested by the MD Anderson researchers -- 251 patients with pancreatic cancer (five of whom had very early lesions), 32 with chronic pancreatitis and 120 healthy controls -- aren't nearly large enough to draw such conclusions. And getting a clear answer, Venook said, would probably require lengthy and expensive studies on very large populations.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "In addition to quoting from the study in Nature\u00a0and an editorial published alongside it,\u00a0the article includes an independent expert who provides a measured and objective assessment of the finding which helps put the study in better context. While stating that the research is \u201ca cool observation,\u201d he added that \u201cthis is not a biomarker yet\u201d since the study was too small to draw a conclusion.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070723/23healytip.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story did mention where the research was conducted and the journal in which it was published.\u00a0 However, it did not contain any obvious input from experts in the field.", "answer": 0}, {"article": "\"With every pulse of your heart, you are pushing blood into these very small blood vessels in the brain,\" he says.\nAt least two large studies have revealed an alarming trend among stroke patients, Koroshetz says.\nIf people knew about the link between dementia and high blood pressure, they might be more inclined to do something about it, Koroshetz says.\nKoroshetz's campaign is getting some help from the Alzheimer's Association.\nAnd he says other people with high blood pressure should follow his lead.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an official of the Alzheimer\u2019s Association, which has an obvious interest in the prevention and treatment of AD. But NPR would have added much credibility to the story with some cautionary note from outside sources about the nature of the evidence for blood pressure control and AD prevention.", "answer": 0}, {"article": "Merck & Co. and Schering-Plough Corp. said a long-awaited trial showed their cholesterol drug Vytorin failed to slow progression of heart disease better than a cheaper drug, threatening the companies' $5 billion-a-year cholesterol-fighting franchise.\n\nSchering-Plough's shares fell 8% to $25.52 and Merck declined 1.3% to $59.78 at 4 p.m. in New York Stock Exchange composite trading.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story included interview quotes from individuals involved in the field of cardiovascular outcomes research, cardiologists, and company spokespeople.", "answer": 1}, {"article": "One found improvement in infants given fennel extract compared to infants given a placebo; another found that infants given a tea containing chamomile, vervain, licorice, fennel and balm-mint seemed to work; while a third found infants given a tea containing fennel, lemon balm and chamomile cried less than infants given a placebo.\nAll of the trials reviewed had \"major limitations,\" such as having too few patients, relying on parental reports of symptoms, or the study design (such as not being double-blinded).\nColic usually starts when a baby is about three weeks old, said Dr. Ari Brown, a pediatrician in Austin, Texas, and author of the Expecting 411 book series.\n\"The notion that any form of complementary and alternative medicine is effective for infantile colic currently is not supported from the evidence from the included randomized clinical trials,\" the researchers from the United Kingdom wrote.\nBecause pediatricians can't offer parents much help with it -- for the most part, babies grow out of colic in time -- desperate parents often turn to alternative or complementary treatments, according to the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story tapped two independent experts: Dr. Andrew Adesman, chief, developmental and behavioral pediatrics at the Steven and Alexandra Cohen Children\u2019s Medical Center of New York and\u00a0Dr. Ari Brown, an Austin pediatrician and co-author of\u00a0Baby 411. Both provided good context and words of caution for concerned parents.", "answer": 1}, {"article": "Using the Clinformatics Data Mart, a database of one of the largest commercially insured populations in the U.S., Baillargeon and colleagues examined data of 450 men aged 40 to 63 with COPD who began testosterone replacement therapy between 2005 and 2014.\nThe paper is currently available in Chronic Respiratory Disease.\n\"We found that testosterone users had a greater decrease in respiratory hospitalizations compared with non-users.\n\"The findings suggest that testosterone replacement therapy may slow the progression of disease in men with COPD.\"\nThe goal of the study was to find out whether testosterone replacement therapy reduced the risk of respiratory hospitalizations in middle-aged and older men with COPD.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funders of the study are not named in the release. The lead author, we learn in the full paper, \u201chas received payment, for consulting, from AbbVie, Endo Pharmaceuticals, GlaxoSmithKline Pharmaceuticals, and Auxilium Pharmaceuticals.\u201d\u00a0Some of these companies manufacture testosterone replacement therapy.\u00a0 This was not mentioned in the news release.", "answer": 0}, {"article": "Statin use may also lead to:\n\u2022 Decreased fibrosis (hardening or scarring of tissue),\n\u2022 Less development of fatty liver,\n\u2022 Slowed or halted spread of hepatitis C virus,\n\u2022 Improvement of portal hypertension (high blood pressure in the liver\u2019s blood vessels),\n\u2022 Destruction of existing liver tumor cells, and\n\u2022 Reduced risk of developing liver cancer.\nNOTE TO JOURNALISTS: To schedule an interview with a member of the research team, please contact the APS Communications Office or 301-634-7209.\nThe article is published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\nThe Society represents more than 10,500 members and publishes 15 peer-reviewed journals with a worldwide readership.\nThe researchers acknowledge that statin drugs can contribute to liver damage in some people, but for people with advanced liver disease, \u201c[s]tatins are cost-effective, generally well-tolerated by patients and the benefits of statin treatment in most patients outweigh their potential hepatotoxic risk.\u201d\n\nRead the full article, \u201cRationale for the use of statins in liver disease\u201d published ahead of print in the American Journal of Physiology\u2014Gastrointestinal and Liver Physiology.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Since this was based on a review article we don\u2019t require a named funding source to rate this satisfactory. Nor do we have any evidence that the authors have any conflicts of interest. If there was, we would expect the news release to include them. ", "answer": 1}, {"article": "Iowa Democrats may have saved the caucuses\n\nIf the proposed Democratic plan is adopted, the Iowa Democratic caucuses will be both familiar and new and may well endure as first in the nation.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Multiple sources are quoted.", "answer": 1}, {"article": "July 14, 2010 -- An experimental weight loss drug that targets the brain\u2019s hunger center was shown to be safe and effective for helping dieters shed pounds in a two-year study, researchers say.\nHe says that all the patients in the study were monitored closely for heart valve irregularities, and no difference was seen in the two treatment groups.\nThe study appears in the July 15 issue of the New England Journal of Medicine.\nThe company hopes to win FDA approval to market the new drug later this year.\nAll the participants were counseled about diet and exercise.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It identifies conflicts in some cases, but there is no truly independent expert source quoted in the story \u2013 something that was badly needed.\u00a0", "answer": 0}, {"article": "But another finding from that study sheds an interesting light on one of 5-Hour Energy\u2019s central claims \u2014 that the energy shot, unlike competitors\u2019, produces \u201cNo Crash Later.\u201d\n\nAccording to the study, 24 percent of test participants who received 5-Hour Energy had reactions similar to a \u201cmoderately severe crash that left them extremely tired and in need of rest, another drink or some other action,\u201d lawsuit filings show.\nBut she declined to say why the results of the study, which was apparently conducted five years ago, had not yet appeared.\nShe added that another study showing the benefits of 5-Hour Energy was undergoing \u201cpeer review\u201d for possible publication in a scientific journal.\nWhatever the case, the energy drink boom has come full circle in Asia, the region where it started.\n\u201cI don\u2019t believe that it is misleading,\u201d said Ms. Lutz, who added that the advertising division of the Council of Better Business Bureaus had approved the \u201cNo Crash Later\u201d claim.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A number of independent sources are quoted in the story.", "answer": 1}, {"article": "In the United States, an estimated 42,000 corneal grafts a year are performed using tissue from posthumous donors, but there are sometimes problems with rejection and experts say failure rates are significant.\nMade from parallel strands of the protein collagen, it refracts light to focus images on the retina.\nThe scientists, whose work was published Wednesday in the Science Translational Medicine journal, said their findings offered hope for the millions of people who go blind each year because of a worldwide shortage of corneas for donation.\nThe biosynthetic corneas also became sensitive to touch and the treated eyes began producing normal tears, the researchers said.\n\u201cThis study ... is the first to show that an artificially fabricated cornea can integrate with the human eye and stimulate regeneration,\u201d said May Griffith of the Ottawa Hospital Research Institute, who led the study.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources. The story does make the effort of explaining that a biotech company provided the substance used to create the corneas, giving readers a hint that this could be primarily a commercial enterprise.", "answer": 0}, {"article": "May 17, 2012 -- An extract from the Chinese herb kudzu may help drinkers cut down on drinking, according to a new pilot study.\nThe study is published in Drug and Alcohol Dependence.\n\"They still drank, but they drank less.\"\nHe studied the extract puerarin.\nIt is one of the substances known as isoflavones found in kudzu.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story points out the extensive links between the manufacturer of the supplement and the study authors. It consults an independent expert who injects an important note of skepticism into the coverage.", "answer": 1}, {"article": "Doctors in Seattle cured a late-stage cancer patient after tinkering with his body's defenses against infection, leading to cautious optimism about treating late-stage melanoma, a deadly skin cancer.\n\nThe surprising result, published in this week's issue of the New England Journal of Medicine, is the latest hopeful finding from the 30-year-old field of \"adoptive immunotherapy,\" which theorizes that the body can be taught to fight off its own cancers.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\nThe article quotes two scientists\u2014the lead researcher on the published paper and the chief surgeon at the National Cancer Institute, an investigator involved in another study that the news story mentioned. Neither is an independent source. \n", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070408/16healy.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The writer notes her prior position as director of NIH, and cites the chief of the Women's Health Initiative branch of NIH. ", "answer": 1}, {"article": "\"If someone said to my husband, 'I know this has been a rough road for you, and a big impact on your sex life, but if she stays on it another five years.\nThat's significant, given that tamoxifen is used by hundreds of thousands of women worldwide, says Gray, whose study was presented Wednesday at the annual San Antonio Breast Cancer Symposium.\nBecause the study didn't include AIs, doctors can't say how whether tamoxifen would benefit women who've taken them, Litton says.\nSome women will be glad to have another treament option, says breast cancer survivor Lillie Shockney, 59, administrative director of the Johns Hopkins Cancer Survivorhip Program in Baltimore.\nThese drugs are slightly more effective than tamoxifen, although they don't work before menopause, Litton says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "THIS IS A CORRECTED COMMENT IN RESPONSE TO A COMPLAINT BY THE REPORTER OF THE STORY \u2013 HER COMMENTS IN THE COMMENTS SECTION BELOW.\nWE INITIALLY SAID THERE WAS NO QUOTE FROM ANY INDEPENDENT EXPERT NOT CONNECTED TO THE STUDY.\u00a0 THAT WAS INCORRECT.\nHOWEVER, OUR CRITERION IN THIS CATEGORY READS: \u201cIn order to get a satisfactory score on this criterion, two things must occur: There must be an independent expert source quoted (someone not directly connected with the research) and there must be some attempt to let the public know about potential conflicts of interest.\u201d\nAND WE POST MORE BACKGROUND ON THIS CRITERION HERE.\nThis story DID NOT include reference to partial funding of the study by AstraZeneca, which produces a brand of tamoxifen. The competing stories by the NY Times and AP did report on AstraZeneca funding. AP went further in pointing out that the study leader \u201chas been a paid speaker for a company that makes one of the drugs.\u201d\u00a0\u00a0\u00a0 So the score remains unsatisfactory despite our initial error (corrected) on the first point.\nThe interview with the administrative director of the Johns Hopkins Cancer Survivorhip Program about her own experience with tamoxifen use added important perspectives. (The reporter apparently missed that we referred to this in a positive note all along.) ", "answer": 0}, {"article": "The American Congress of Obstetricians and Gynecologists, for example, recommends that regular screenings begin at age 40, while the American Cancer Society calls for women to start yearly screening at age 45 and then move to screening every two years starting at age 55.\nFran Visco, president of the National Breast Cancer Coalition, said the task force's guidelines for women in their 40s \u2014 that they should discuss whether to get mammograms with their doctors and make individual decisions \u2014 come closest to following the evidence accumulated over the past three decades.\nThe task force first suggested in 2009 that breast cancer screening begin at 50 instead of 40, touching off enormous criticism.\nSeveral groups that lobbied for congressional action said in a statement last month that the task force recommendations conflict with those of other organizations.\nDespite the decades of marketing of mammography to women, \"women are capable of understanding the complexities of the issue, evaluating the evidence and making their own health decisions,\" she said in a statement.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story incorporates input from several independent sources. Comments from Fran Visco of the National Breast Cancer Coalition are worth repeating: \u201cWomen are capable of understanding the complexities of the issue, evaluating the evidence and making their own health decisions.\u201d", "answer": 1}, {"article": "I am cancer-free,\" he says.\nIf Lazarus hadn't had any studies, says Dr. Harvey Pass of the NYU Medical Center in New York, the tumor would have grown causing pain, cough bleeding and maybe not have been able to be surgically removed.\nBut doctors decided to use a more sophisticated test \u2014 a CT scan that can detect tumors as small as a kernel of rice.\nSays Henschke: \"This is a way of finding it early and taking it out early, because it is a much better chance of being cured from the disease.\"\nThat's because standard chest X-rays too often can't spot it until it's too late, reports.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes the prinicpal investigator of the study about the benefits of screening. Although the story quotes another physician, he only discusses his patient's case, not the concept of lung cancer screening.\u00a0 Some independent perspective was needed on this important topic. ", "answer": 0}, {"article": "Dr Carol Routledge, from Alzheimer's Research UK, said: \"The diseases that cause dementia begin in the brain up to 20 years before any symptoms start to show, presenting a vital window of opportunity for us to intervene before widespread damage occurs.\nAs a final test, it was given a set of 40 scans from 40 patients it had never studied before.\nThe research is published in the latest issue of the journal Radiology.\nBoffins from the University of California trained the computer using more than 2,100 scans from 1,002 patients.\nIt proved to be 100 percent accurate at detecting Alzheimer's disease many years before the patient was later diagnosed.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes that were collected by the Science Media Centre, yet this wasn\u2019t disclosed. The other quote was from the news release, which also wasn\u2019t attributed.", "answer": 0}, {"article": "Toenail fungus causes nails to become thick, yellow and brittle in a way that looks pretty ugly and can be painful.\nIn this case, there is a chance.\u201d\n\nEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\n\u201cI\u2019ve had patients come in who have had laser procedures and not seen long-term success.\u201d\n\nFirestone also says that over-the-counter antifungal nail creams and ointments rarely work because they can\u2019t penetrate the nail root.\nResearch done by PinPointe, which is based in Chico, Calif., identified more than 100 organisms, including fungi, yeast, mold and bacteria, that work together to cause toenail fungus.\nIt tends to be a cosmetic issue for the younger set and a pain issue for older folks.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are multiple sources quoted and some are critical of laser treatment, but, on balance we thought too much weight was given to a conflicted physician and a conflicted study. The physician who is quoted the most frequently is heavily selling these treatments. And the only study presented as proof of the laser treatment\u2019s efficacy is also the only study being promoted on the website of the company highlighted in the story, PinPointe USA. The author of that study is\u00a0the head of\u00a0PinPointe\u2019s Advisory Panel. http://pinpointefootlaser.com/news-and-events/press-releases/dr-adam-landsman-appointed-head-of-pinpointe-usas-advisory-panel\u00a0This should have been noted in the story.", "answer": 0}, {"article": "\"It wasn't a huge, overwhelming difference,\" O'Neil said.\nThe study's 563 participants were all overweight or obese and under a doctor's care for uncontrolled Type 2 diabetes.\nThe other half went to Weight Watchers meetings, had access to Weight Watchers' online materials and had two phone consultations and follow-up email contact with certified diabetes educators who told them how to modify the Weight Watchers plan to help with their diabetes.\nO'Neil said because Weight Watchers has centers all over the country, including sites in small towns with limited or no medical facilities, its program could help meet this need if combined with diabetes-specific counseling.\nParticipants had four follow-up visits related to the study and continued to see their regular doctors for medical management of their diabetes.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release makes clear that Weight Watchers funded the study but does not disclose the lead investigators other financial ties to Weight Watchers. The published study states that several of the authors were Weight Watchers employees, held stock in the company, served on its board or were Weight Watchers product patent holders.", "answer": 0}, {"article": "\"It's a very important trial,\" added Dr. Angeles Alvarez Secord, associate professor of gynecologic oncology at Duke Comprehensive Cancer Center in Durham, N.C. \"I've been using [the IUD] clinically for several years now for this purpose in patients who desire future fertility and some patients who cannot undergo surgery or who are at high risk for surgical complications.\nNo adverse effects from treatment were noted, according to the researchers, who declared no conflicts of interest.\nThe majority of these women have not yet had children, according to background information in the article.\nThe IUD was removed at the end of the year if there was no evidence of cancer.\nBakkum-Gomez has also used the method in her practice and is conducting a study of the IUD, which was originally designed as a contraceptive device, for this purpose.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes several independent experts and notes that none had a conflict of interest.", "answer": 1}, {"article": "[4] Quotes direct from author and cannot be found in text of Article.\nThis study was funded by Knut and Alice Wallenberg Foundation and the Swedish Research Council.\n\"This is the first study of its kind which is based on a very large study sample, and is not limited to specific populations, single types of risk, or requiring laboratory testing.\"\nThe resource has been open to bona fide health researchers for 18 months.\nThe score, which uses measures that can be obtained by simple questionnaires without any need for physical examination, such as self-rated health and usual walking speed, could be used by individuals to improve awareness of their health status, and by doctors to identify high-risk individuals for further treatment, say the authors.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funders are clearly identified in the notes at the bottom of the press release.\u00a0 The investigators assert the absence of conflicts of interest in the journal article itself.", "answer": 1}, {"article": "It can dominate the lives of patients and their families, leading to excessive overeating, choking, and stomach rupture, along with slowed metabolism and psychiatric disorders.\nThomas E. Hughes, chief executive of Zafgen, said the Boston company will use the data to prepare a \u201crisk-mitigation\u201d plan to help persuade the Food and Drug Administration to lift its so-called clinical hold on the late-stage trial, allowing it to resume.\nBut he conceded that Zafgen, which had once hoped to begin selling its drug candidate, Beloranib, as early as 2016, will have to conduct at least one additional study before it can apply for FDA approval.\nSixty-eight of the enrolled patients completed the study, Kim said, while 27 other patients completed 20 of the trial\u2019s scheduled 26 weeks.\n\u201cThis is the first demonstration of a clinical benefit against two of the major issues that affect this patient population.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two sources appeared to have been interviewed for this piece, Dr. Hughes and Dr. Butler. The former is the chief executive of Zafgen while the latter is a medical researcher serving as a principal investigator of the clinical trial at the University of Kansas Medical Center. To meet our standard here, the story would have had to interview a source completely independent of the company and the trial. We rate this Not Satisfactory, but at least the article makes it clear that the studies under consideration are for a commercial drug.", "answer": 0}, {"article": "Surgery also typically involves significant breast tissue damage and disfigurement due to large incisions and removal of sizable breast mass.\nPatents will be followed for five years to ensure they remain cancer free.\nDeveloped by a diverse, esteemed scientific advisory board, the trial is underway at 20 carefully selected sites throughout the United States.\nThe ICE3 trial, which began patient enrollment in October 2014, will significantly expand data on the technique as a treatment for breast cancer.\nFollowing numerous limited studies, a growing number of women are now being treated with the technique as part of a groundbreaking clinical trial involving leading breast cancer specialists across the country.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "IceCure Medical, the manufacturer of ICE3, is named as the source of the\u00a0release.", "answer": 1}, {"article": "In 2016, breast cancer accounted for 29 percent of all new cancers identified in the United States and was responsible for 14 percent of all cancer-related deaths.\nAABGU, which is headquartered in Manhattan, has nine regional offices throughout the United States.\nVisit vision.aabgu.org to learn more.\n\"Our new approach utilizing urine and exhaled breath samples, analyzed with inexpensive, commercially available processes, is non-invasive, accessible and may be easily implemented in a variety of settings.\"\nStudy contributors include: Ben-Gurion University biomedical engineering researchers Prof. Yehuda Zeiri, Or Herman-Saffar, Zvi Boger, and Raphael Gonen; Dr. Shai Libson, a surgeon in the Breast Health Center at Soroka; and Dr. David Lieberman, an associate professor in Ben-Gurion University's Joyce and Irving Goldman Medical School, Faculty of Health Sciences.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release does not give us information on funding or conflicts of interest. The full journal article states there are no conflicts.", "answer": 0}, {"article": "Their median age was in the mid-50s, and they were followed for a median of 6.3 years.\n\u201cThis is such a radical change in thought that it\u2019s been hard for many people to get their heads around it,\u201d said Dr. Monica Morrow, chief of the breast service at Sloan-Kettering and an author of the study, which is being published Wednesday in The Journal of the American Medical Association.\nIt\u2019s hard for us as surgeons and medical oncologists and radiation oncologists to accept that you don\u2019t have to remove the nodes in the armpit.\u201d\n\nDr. Grant W. Carlson, a professor of surgery at the Winship Cancer Institute at , and the author of an editorial accompanying the study, said that by routinely taking out many nodes, \u201cI have a feeling we\u2019ve been doing a lot of harm.\u201d\n\nIndeed, women in the study who had the nodes taken out were far more likely (70 percent versus 25 percent) to have complications like infections, abnormal sensations and fluid collecting in the armpit.\nTwo other breast surgeons not involved with the study said they would take it seriously.\nThe results mean that women like those in the study will still have to have at least one removed, to look for cancer and decide whether they will need more treatment.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Good quotes including from Dr. Monica Morrow, chief of the breast service at Sloan-Kettering and an author of the study, but also a few fromindependent experts toward the end.\u00a0Dr. Grant W. Carlson, a professor of surgery at the Winship Cancer Institute at Emory University, and the author of an editorial accompanying the study, provides some soul-searching context by saying that, in taking out so many lymph nodes, \u201cI have a feeling we\u2019ve been doing a lot of harm.\u201d\u00a0Dr. Elisa R. Port, the chief of breast surgery at Mount Sinai Medical Center in Manhattan, said, \u201cIt\u2019s definitely practice-changing.\u201d And\u00a0Dr. Alison Estabrook, the chief of the comprehensive breast center at St. Luke\u2019s-Roosevelt hospital in New York said, \u201cIn the past, surgeons thought our role was to get out all the cancer. \u2026 Now he\u2019s saying we don\u2019t really have to do that.\u201d", "answer": 1}, {"article": "\u2022 Women with a 20 percent or greater lifetime risk of breast cancer also should undergo screening MRIs.\nThe new study involved more than 900 women.\nFifty percent of these women met either the ACS or the ASBS requirements for early mammography, Plichta said.\nPlichta was to present her team's findings Thursday at the American Society of Breast Surgeons annual meeting in Dallas.\nAll were seen as new patients at the Massachusetts General Hospital breast clinic between March 2011 and October 2015, the researchers said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only a study authors appear to have been interviewed for the story.", "answer": 0}, {"article": "Massage therapy increases the activity level of the body's white blood cells that work to combat viruses.\nThe association is directed by volunteer leadership and fosters ongoing, direct member-involvement through its 51 chapters.\nEVANSTON, Ill., Nov. 4, 2015 /PRNewswire/ -- People looking to fend off cold and flu as the winter months arrive should speak to a massage therapist about prevention strategies.\nAccording to research from Cedars-Sinai, participants in a Swedish massage group experienced significant changes in lymphocytes, which play a large role in defending the body from disease.i A lymphocyte is one of the three subtypes of white blood cells in the immune system.\nImmediate massage benefits included reduced anxiety while the long-term impact increased serotonin values, natural killer cell numbers and lymphocytes,iii which work to strengthen the immune system and cognitive function during sickness.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release doesn\u2019t list who the funders were for each study and whether there were any conflicts of interest.\nThe release is clearly identified as coming from a professional association and it\u2019s evident its purpose is to drive new customers toward association members.", "answer": 0}, {"article": "Women choosing to have both breasts removed face higher surgery costs and slightly higher risks of post-surgery complications and infections.\nHe hopes women aren\u2019t making the choice believing it will result in longer life, because the evidence is sketchy at best.\nWhile these suspicions rarely end up as cancer, they do often result in follow-up tests such as biopsies and ultrasounds that can frighten patients, Leach said.\nIt\u2019s an emotional decision that women often make quickly, considering that surgeries often take place within days of their cancer diagnosis.\nThe survey results came a decade ago, however, when the safety of breast implants was a major issue, said Mayo\u2019s Dr. Lynn Hartmann.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The reporter interviews the lead author of the study, two additional credible medical experts and one patient. The patient, a nurse, is a more credible source than one often finds in news stories.\u00a0\u00a0 ", "answer": 1}, {"article": "People with abdominal obesity are at higher risk of heart disease and early death than people with slimmer waistlines.\nThat intensity was equivalent to brisk walking for the previously sedentary participants, Ross told Shots.\nIn effect, those guidelines say there's no particular benefit from working out harder, other than saving time.\nThe intensity was about equivalent to walking slowly, said study author Robert Ross, a kinesiologist at Queen's University.\n(Note that we're not talking about the all-out sprints of high-intensity interval training.)\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an exercise expert who was not affiliated with the study. He provides some useful context on the value of strength training.", "answer": 1}, {"article": "\"We have the side view and the back view,\" said Kaufman.\nThis new wave of radiology-based colonoscopy could improve those odds further.\nDr. Arie Kaufman of SUNY Stony Brook demonstrated the virtual colonoscopy for CBS New York's Dr. Max Gomez.\nDoctors can then \"walk through\" the colon and explore many different angles.\nHe added it could lead to better and earlier detection of colon polyps.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The CBS story quotes only one source, Dr. Arie Kaufman, and does not disclose the fact that he also happens to have invented the technology. An independent expert, who could have talked about the limitations of virtual colonoscopy and the benefits of traditional colonoscopy, would have been helpful.", "answer": 0}, {"article": "Broccoli has been linked to a growing list of health benefits, such as a reduced risk of cancer and osteoporosis. New research suggests consuming broccoli could also slow or reverse blood-vessel damage and atherosclerosis due to high cholesterol.\n\nThe study, in Experimental Biology and Medicine, found that a high-cholesterol diet combined with supplements containing sulforaphane, a natural compound in cruciferous vegetables such as broccoli and Brussels sprouts, significantly reduced levels of LDL, the so-called bad cholesterol,...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story included no quotes from the researchers or outside sources\u2013both could have provided important context and caveats about this kind of early-stage animal research, and the emerging results of this chemical, which also made recent headlines in cancer research, making us curious about why this study, now.\nAs for conflicts of interest, the article didn\u2019t mention any, and because the study coauthors declare none, we will assume that to be the case.", "answer": 0}, {"article": "The risks of prostate removal, or prostatectomy, are well known and include higher chance of developing incontinence and erectile dysfunction.\nThe study was funded by the New Jersey Health Foundation, the National Cancer Institute (P30 CA-072720 and CA-116399 and the Rutgers Cancer Institute of New Jersey Biometrics Shared Resource.\nThe research was published September 25th in the journal Cancer.\n\"For high-risk prostate patients we started the use of aggressive radiation therapy after surgery 20 years ago,\" said Adam Dicker, Senior Vice President and Chair of the Department of Enterprise Radiation Oncology at Jefferson Health, who was not involved in the study.\nThey matched the comparison groups by age, race and co-morbidity to control for factors that may influence patient outcomes, and analyzed which group did better 10 to 15 years after their procedures.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release stated that the study was funded by the New Jersey Health Foundation, the National Cancer Institute, and the Rutgers Cancer Institute of New Jersey Biometrics Shared Resource.", "answer": 1}, {"article": "Computed tomography coronary angiography (CTCA), is a high-resolution X-ray of the heart that can be used to diagnose the reason for angina, or chest pain, symptoms and clarify what other treatments might be needed.\nThis reflects the fact that the cause of the symptoms had been unknown before and in addition they now have heart artery disease that needs treatment, Newby said.\nIf a doctor is faced with a patient who is already on an aspirin and statin with an unconfirmed and questionable clinical diagnosis of angina due to coronary heart disease, he said, then CTCA would be useful because finding normal heart anatomy means that more invasive testing can be avoided, treatment could be stopped and quality of life improved.\n\u201cIn my opinion, CTCA does have added value in the diagnostic process (improved decision making), it is less invasive than coronary angiography (CAG), and can provide more clarity in the cardiac symptoms experienced by patients,\u201d Mommersteeg concluded.\n\u201cIf, however, a patient presents with atypical symptoms and is on no therapy, then the clinician needs to discuss with the patient the implications of potential CTCA findings, including nonobstructive disease that would mandate life-long preventative therapy,\u201d Newby said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There is an independent source quoted. However, the story does not mention that the senior researcher quoted throughout the story had disclosed \u201chonoraria and consultancy from Toshiba Medical Systems,\u201d a manufacturer of CT scanners. There is also no mention of the funding of the study, though the funding description in the journal article says it came from a mix of public agencies and foundations, not from an industry source.", "answer": 0}, {"article": "While mammography works on breast density, radiofrequency looks at contrasts between normal and diseased breast tissues.\n\u201cAlthough there is still research to be done, the system has great potential to bring a new way for breast cancer diagnosis.\u201d\n\nCarolyn Rogers, clinical nurse specialist at Breast Cancer Care in the U.K., says in an emailed statement: \u201cEvidence is needed to demonstrate the accuracy and uses of this device.\nThe real-time imaging minimizes the chance of missing a breast tumor during scanning.\u201d Wu says it will even work through a bra.\nCosts are reduced and the electronics fit into a case the size of a lunchbox.\nRadiofrequency or microwave technology for breast cancer detection is not new, but what Zhipeng Wu, PhD, from Manchester\u2019s School of Electrical and Electronic Engineering has achieved is the speed of results and portability.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An independent source was consulted. Talking to more of them, or giving more space to Ms. Rogers\u2019s keen caveats about the uncertainty and context, instead of burying them like an appendix, may have reversed some of our unsatisfactory ratings.\nThe article is honest, at least, that it sourced a news release. Ideally it would have acknowledged that all the factoids and forward-looking upside in the article came from Dr. Wu and the university, those who presumably hold the patent on this tool and stand to profit financially from good press or success in the IET awards competition. ", "answer": 1}, {"article": "Schafer Cardiovascular Research Fund, the Johns Hopkins Magic That Matters Research Fund for Cardiovascular Research, grants from the National Center for Advancing Translational Sciences (UL1-TR-000040 and UL1-TR-001079), and contracts from the National Heart, Lung, and Blood Institute (HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169).\nBut not all people deemed \"higher risk\" by traditional methods may need to be aggressively treated, McEvoy says.\n\"It may be that if patients are in that blood pressure treatment gray zone with a high risk score but their coronary artery calcium score is zero, then they don't need to be treated aggressively to 120 millimeters of mercury and can be treated to 140 instead,\" says McEvoy.\nAnd the risk factor equations that determine whether certain people are at higher risk and should be treated more intensively with blood pressure medications may have inaccuracies on the individual level, says McEvoy.\nAdditional authors on the study included Seth Martin, Zeina Dardari, Wendy Post, Khurram Nasir and Michael Blaha of Johns Hopkins; Michael Miedema of the Minneapolis Heart Institute; Veit Sandfort of the National Institutes of Health; Joseph Yeboah of Wake Forest Baptist Health; Matthew Budoff of the University of California, Los Angeles; David Goff of the Colorado School of Public Health; and Bruce Psaty of the University of Washington.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release mentions who funded the study, but it omits one potential conflict of interest that was reported in the study: one of the authors serves on a speakers\u2019 bureau for GE Healthcare, which makes imaging equipment and software designed to detect coronary artery calcification. It\u2019s not a a major concern, but the lack of disclosure means the release doesn\u2019t quite meet our standard here.", "answer": 0}, {"article": "But such removal is painful, makes recovery more difficult and leaves women susceptible to complications, including infections and a chronic, sometimes disabling swelling in their arms known as lymphodema.\nIn a telephone interview, Gary Lyman of the American Society of Clinical Oncology said the findings will probably prompt the group to revise its recommendations for breast cancer patients accordingly.\nThe study, involving nearly 900 women who were treated at 115 sites across the country, found that those who did have their lymph nodes removed were no more likely to survive five years after the surgery than those who did not, the researchers reported in a paper published in the Journal of the American Medical Association.\nIn an accompanying editorial, Grant Walter Carlson and William Wood of Emory University in Atlanta called the study an \"important contribution\" that represents the latest development in breast cancer treatment, which has steadily been moving toward less-aggressive options, sparing women from unnecessary surgery and follow-up therapy.\nThe study provides \"strong evidence\" that many women can safely forgo lymph node removal, they wrote.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article included quotes from an editorial accompanying the study and from an independent source at the American Society of Clinical Oncology.\u00a0 While the article did mention that the study was funded by the federal government, it would have been helpful for readers to know that it was funded by the National Cancer Institute.", "answer": 1}, {"article": "In the United States, over 6.7 million adults annually suffer from panic disorder; panic attacks affect a total of 27 million adults in the U.S. every year and are a common component of other anxiety disorders.\nDANVILLE, Calif., April 11, 2018 /PRNewswire/ -- Palo Alto Health Sciences, Inc. (PAHS), developer of the drug-free Freespira\u00ae treatment for panic attacks and other symptoms of panic disorder, today announced that another study has demonstrated clinically significant symptom improvement, with 80% of patients panic attack free one year after treatment.\nSymposium Chair David Tolin, Ph.D., Director of Anxiety Disorders Center, The Institute of Living, and Adjunct Professor of Psychiatry, Yale University School of Medicine, commented, \"Studies of the Freespira treatment have shown that this innovative approach to treating patients suffering from panic symptoms and panic attacks not only significantly reduces or eliminates these symptoms in approximately 80% of patients, but also results in meaningful reduction in health costs.\"\nFreespira is commercially available throughout the U.S. To learn more, visit http://www.freespira.com or contact info@pahealthsciences.com.\nDebra Reisenthel, CEO of Palo Alto Health Sciences, added, \"Patients with panic symptoms and panic attacks have 3-5 times higher medical costs than patients without panic due to higher utilization of medical resources, including ED visits, physician visits and prescription drugs.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "We are not told the source of money for any specific clinical trials. The release was written by Palo Alto Health Sciences, the company that sells the Freespira system. But we aren\u2019t told if the company\u00a0 supported any of the clinical trials financially and without access to the studies, we can\u2019t look up any potential conflicts of interest disclosures.", "answer": 0}, {"article": "They have.\nThere's no official policy from the American College of Cardiology, but officials say most members support screening student athletes.\nAccording to Zipes, \"The adrenalin that is released when you're participating [in sports] can stimulate this abnormally thick heart muscle and cause a fatal heart rhythm problem, that is a very rapid heartbeat with no effective contraction, no blood being ejected to the brain and other organs.\"\nThe severity of this and the other two problems that turned up as a result of the abnormal EKGs are reason enough, Debauche says, to screen all school athletes nationwide.\nCardiologist Douglas Zipes, past president of the American Academy of Cardiology, says the problems kids suffer are typically electrical, like abnormal heart rhythms, or structural, like a thickening of the heart muscle.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\n\nThe story quotes Thomas Debauche, a Houston cardiologist and author of the screening study, and Douglas Zipes, a former president of the American College of Cardiology (ACC), both of whom are supportive of screening. It also mentions that ACC officials say that \u201cmost members\u201d support screening athletes. Although there is a suggestion that there is an opposing point of view, no such voice is quoted in the story. That introduces a clear imbalance. The story should have included the perspective of one of the many experts who would have disputed the wisdom of routine screening. It also could have mentioned that routine screening would result in more office visits and more revenue for cardiologists, thus creating a financial incentive for ACC members to promote the benefits of screening.\u00a0 \n", "answer": 0}, {"article": "MU physicians treat patients from every county in the state, and more Missouri physicians received their medical degrees from MU than from any other university.\n\"Most patients with this disease are older and tend to have other health conditions such as high cholesterol.\n\"However, further research is needed to assess the benefits of using statins before surgical repair of other types of aneurysms.\"\nOf those who do get to a health facility alive, only about 50 percent survive.\nThe bottom line is that patients who used statins were more likely to survive during and after an elective endovascular procedure.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "It appears this epidemiological study received no outside funding so we believe it\u2019s safe to conclude there is no conflict of interest.", "answer": 1}, {"article": "(That\u2019s a high dose; a 3 oz.\nThese are questions Kwong and others hope to answer with more studies.\nThe effects remained strong even after the researchers accounted for the fact that all of the people were taking standard heart disease treatment drugs, including cholesterol-lowering statins and blood pressure medications.\nKwong says that the findings are only the first step toward considering whether omega-3 fatty acid supplements should be part of every emergency heart attack response.\n\u201cBut I do think it\u2019s logical that our results hold promise, and may reduce bad outcomes in patients after a heart attack.\u201d\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Only the lead investigator, Dr. Raymond Kwong, was interviewed.", "answer": 0}, {"article": "A diet that includes tomatoes could lower the chance of having a stroke.\n\nA new study shows that men who had the highest levels of lycopene\u2014an antioxidant found in tomatoes\u2014had fewer strokes than men who had the lowest level of lycopene in their blood. Overall, the risk of strokes was reduced by 55%.\n\nThe study, based in Finland, will be published...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does include a comment from an independent expert, who emphasizes that diet and lifestyle factors are important for stroke prevention. However, there was nowhere near the depth of context provided by\u00a0expert sources in the competing coverage by CNN and WebMD.\nAnd if the expert quoted in this story really said that lycopene \u201cprevents blood clots from forming,\u201d as the story suggests, then he is misinformed. There is no evidence that we\u2019re aware of that shows lycopene prevents blood clots.", "answer": 1}, {"article": "Caucasian men more commonly reported circumcision (69%) than African American men (43%).\nThe bottom line from the American Cancer Society: While this is an interesting finding, it's not likely to spur any change in recommendations or medical practice.\nThe good news, we're told, is that there are many things we can do \u2013 or not do \u2013 in our adult lives to lower our risk of developing different types of cancer.\nIt's important to note, right off the bat, that this study is not purporting to establish a cause and effect relationship.\nBut a new study published Monday in Cancer suggests that at least one decision our parents make FOR us may have an impact on our predisposition to certain types of cancer.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story concludes with a statement attributed to the American Cancer Society suggesting that the findings won\u2019t change medical practice. While this statement is certainly no substitute for an actual conversation with an expert, it\u2019s more context than we see from many similar blog posts about medical studies. We\u2019ll give it a passing grade, though barely.", "answer": 1}, {"article": "Drs.\nThe authors report no conflicts of interest.\nEhsanipoor, Saccone, Seligman, Pierce-Williams, and Ciardulli were the co-investigators with Dr Berghella.\nDr. Berghella and colleagues compiled data from seven small clinical trials that collectively included a total of 1,215 women.\nThis study and others are providing evidence for changes in obstetric practice that could help safely reduce c-section rates.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t note funding sources but the research report indicates that the scientists received no financial support, a situation not uncommon when analyzing existing data. The release does explicitly state that none of the investigators has a conflict of interest.", "answer": 1}, {"article": "Falling whilst skiing, tumbling down the stairs or getting hit on the head can cause symptoms such as blurred vision, vomiting, loss of consciousness or memory for about 30 minutes.\nThese results, patented by UNIGE and awarded the Prix de l'Innovation Academy in December 2017, will be marketed from 2019 by ABCDx, a start-up founded four years ago by Jean-Charles Sanchez of UNIGE and Joan Montaner of Vall d'Hebron Hospital in Barcelona, co-authors of this study.\nHis team has developed a rapid diagnostic test (POCT) called TBIcheck, inspired by the principle of pregnancy testing: by placing a single drop of blood on the well of a small 5cm plastic case, the patient knows within 10 minutes whether there is a risk of mild trauma, namely whether or not his H-FABP level is higher than 2.5 nanograms per millilitre of blood.\nThis discovery, described in PLOS ONE, will not only relieve emergency departments, free patients from often long waits, but also save on costly medical examinations.\n\"We are currently preparing an even more effective TBIcheck, which will allow 50% of patients to be sent home, but which requires an increase in the sensitivity of the test that receives the blood.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release stated that the test sponsor, the University of Geneva, holds a patent on the test which was developed by two of the study\u2019s authors who founded the company that will sell the test.", "answer": 1}, {"article": "Jan. 25, 2010 -- A low-carbohydrate diet may have health benefits that go beyond weight loss.\nResearchers say studies have already shown that the two weight loss methods are effective at promoting weight loss, but it's the first time the health effects of each have been compared head to head.\n\"I expected the weight loss to be considerable with both therapies but we were surprised to see blood pressure improve so much more with the low-carbohydrate diet than with orlistat,\" researcher William S. Yancy, Jr., MD, an associate professor of medicine at Duke University Medical Center, says in a news release.\n\"It's important to know you can try a diet instead of medication and get the same weight loss results with fewer costs and potentially fewer side effects,\" Yancy says.\nA new study shows that a low-carbohydrate diet was equally good as the weight loss drug orlistat (the active ingredient in Alli and Xenical) at helping overweight and obese people lose weight, but people who followed the low-carb diet also experienced a healthy drop in their blood pressure levels.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story\u2019s only quotes come from Dr. Yancy, a researcher affiliated with the study. The story also does not inform\u00a0readers that Dr. Yancy and another co-author on the study have received funding from the Robert C. Atkins Foundation, which promotes\u00a0research on low-carb diets.\u00a0", "answer": 0}, {"article": "He says:\n\n\"When I was diagnosed with early prostate cancer, I had the option of active surveillance but I didn't want to wait until it got worse so when I was offered a place on the trial I signed up straight away.\nThe trial involved 47 treatment sites from ten different European countries, most of which were performing VTP for the first time.\nThe trial was funded by STEBA Biotech which holds the commercial license for the treatment.\nIn the trial only 6% of patients treated with VTP needed radical therapy compared with 30% of patients in the control arm who were under active surveillance.\nThe VTP therapy approach was developed by scientists at the Weizmann Institute of Science in Israel in collaboration with STEBA Biotech, and the European phase I, II and III trials were all led by UCL.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release states that the trial was funded by Steba Biotech, which holds the commercial license for the treatment. However, it does not mention that all of the study authors received compensation from Steba, and some also receive money from other biotech firms.", "answer": 0}, {"article": "\u201cHe said, \u2018Doc, give me what I got last time.\nBut to become standard depression treatment, he said, much more needs to be known.\nUntil there are answers, Zarate of the mental health institute said ketamine should be a last-resort treatment for depression after other methods have failed.\n(AP Photo/Teresa Crawford)\n\nCHICAGO (AP) \u2014 It was launched decades ago as an anesthetic for animals and people, became a potent battlefield pain reliever in Vietnam and morphed into the trippy club drug Special K.\n\nNow the chameleon drug ketamine is finding new life as an unapproved treatment for depression and suicidal behavior.\nKhare became intrigued and earlier this year began offering ketamine for severe depression at an outpatient clinic he opened a few years ago.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story used a range of sources. It noted that one source, Yale University psychiatrist Gerard Sanacora, PHD, MD, has worked for companies seeking to develop ketamine-based drugs.\nOne quibble: The story devoted substantial ink to positive anecdotes. Was the reporter able to find patients with negative experiences involving ketamine? That would be interesting to know.", "answer": 1}, {"article": "The Food and Drug Administration does not endorse DHA or fish oil capsules, but recognizes doses of up to 3 grams a day of fish oil as generally safe.\nThe study was financed in part by Martek, a concern that manufactures DHA, and one author received a grant from Pfizer, France.\nDr. Ernst J. Schaefer, the lead author of the study, was cautious in interpreting the results.\n\u201cThis study doesn\u2019t prove that eating fish oil prevents dementia,\u201d he said.\nFatty fish, he said, is best, and frying will cause DHA to deteriorate.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story was based on information from an original research study and included quotes from the study senior author as well as material from an editorial about the research study.", "answer": 1}, {"article": "Texting also played a role in helping patients feel like they were in control of their treatment, particularly during the first month.\nThe findings were released at the American Society of Clinical Oncology meeting in Chicago.\nThe text messages were most effective at reducing distress at the 2- and 4-month marks, according to the data presented by chief author Kuang-Yi Wen, an assistant professor in the Cancer Prevention and Control program at Fox Chase.\nAt the fourth month mark, \u201cthe gap was huge\u201d between the texting and control groups, she told Reuters Health in a telephone interview.\nThe feasibility study was designed to see if texting could relieve some of the anxiety that comes with the fatigue, hair loss and other body changes that can accompany anticancer drugs.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There were no independent sources. While we couldn\u2019t identify any conflicts of interest, some of the researchers receive payments from industry. The article fell short by not indicating who funded the study.", "answer": 0}, {"article": "\"It's an important step along the way,\" Dr. Hadley said.\nBut Dr. Ravussin and Dr. Hadley cautioned that the study was preliminary, and that it did not prove that calorie restriction could make people healthier or add years to their lives.\nHe called the results \"striking,\" even though the experiment was only a pilot study for a two-year trial of calorie restriction due to begin in the fall.\nAmong the main findings of Dr. Ravussin's study was that calorie restriction led to decreases in insulin levels and body temperature.\nDr. Ravussin's study included men and women, ages 27 to 49, who were overweight but not obese.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The main expert quotes in the story came from people with a vested interest in showing positive results. Evan Hadley of the National Institute on Aging (source of funding for the study) called the results of this pilot study \u201cstriking\u201d. In addition, an estimate for the number of individuals currently engaging in calorie restriction appears to have been obtained from the president of the Calorie Restriction Society. While this study is one of three pilots studies for the feasibility of calorie restriction in humans, no comments from the other research groups was included. ", "answer": 0}, {"article": "Patients with chest pain symptoms require multiple blood tests over several hours before a diagnosis is reached.\nIn this international study, researchers from Canada, Australia, New Zealand and Germany combined common laboratory blood tests available at many hospitals around the world to create a single laboratory score, or clinical chemistry score, to diagnose heart attack.\nThe score, published in CMAJ (Canadian Medical Association Journal), can also identify patients at risk of subsequent heart issues after discharge.\n\"Adoption of the clinical chemistry score algorithm would standardize reporting of high-sensitivity cardiac troponin test results, how the tests are interpreted in the normal range, and represent an option less susceptible to both analytical and preanalytical errors.\nAccording to Professor Andrew Worster, also from McMaster University, \"This lab score may reduce both the number of blood tests and time spent in the emergency department for chest pain patients.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funder\u2014the Canadian Institutes for Health Research\u2014is clearly identified.\u00a0 Conflicts of interest among the many coauthors, however, are not mentioned.\u00a0 The original research article offers a lengthy list of potential conflicts; for example, the two coauthors quoted in the news release have begun the process of patenting the laboratory scoring system discussed in the research.\u00a0 And the first author of the paper, one of those quoted, has received research funding and honoraria from a number of drug companies.", "answer": 0}, {"article": "\"This is quite good news,\" Fauci said.\nBut different manufacturers make different formulations of the vaccine, so more evidence was needed.\nThe report from the Centers for Disease Control and Prevention Friday also came with good news: Testing of vaccines for swine flu show that they work with a single dose and take effect rapidly.\nCSL, which is one U.S. vaccine supplier, found the same side effects in its study that people experience with regular flu vaccine, which is no surprise since this shot is merely a recipe change from the annual standby.\nPlus, the U.S. work shows that people are protected eight to 10 days after that inoculation, he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThis story points out that several of the trials were done by vaccine manufacturers. It quotes government officials who were not directly involved in those trials. However, as noted above, the story is a primarily summary of official statements. There are no quotes from independent experts in infectious diseases.", "answer": 1}, {"article": "\"The next questions are, 'how do we increase the number of patients who respond?'\n\"The overall survival benefit shown in this study sets a new benchmark for therapeutic strategies for advanced RCC patients in need of a second-line therapy.\"\nThe study included 821 patients with advanced RCC across 151 sites in 24 countries in North America, Europe, Australia, South America and Asia.\nFurther, among patients who showed a response, the impact was \"durable,\" according to Sharma.\nPublished online by the New England Journal of Medicine and being presented this week at a Presidential session of the European Cancer Congress (ECC), the findings of CheckMate-025 provide definitive evidence that an immune checkpoint inhibitor is a valid treatment strategy for patients with advanced RCC, and supports a paradigm change in the standard of care treatment, according to the authors.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release fails to note that the study was funded by the manufacturer of nivolumab (Bristol Myers Squibb) and that Dr. Sharma is a consultant to the company. This is important context.", "answer": 0}, {"article": "Drinking cow\u2019s milk produced at night may be a treatment for anxiety and insomnia, suggests an animal study in the Journal of Medicinal Food.\n\nA glass of milk at bedtime has long been touted as a sleep aid. But the study found that milk collected at night, or night milk, had enhanced sedative effects in mice compared with milk produced during the day. Night milk significantly decreased the rodents\u2019 physical activity, balance and coordination and increased sleep time compared with day milk, the research showed.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources are solicited.\u00a0The only link included to an outside \u201csource\u201d is to the company that sells night milk.", "answer": 0}, {"article": "For example, she says, someone might say, \" 'I find that I'm staying in my room, not answering the phone, not answering texts, not answering emails.'\nHe says she also agreed to use a crisis help line if things escalated.\nThat follow-up is key, says Julie Goldstein Grumet, a psychologist at the Zero Suicide Institute at the Education Development Center, a Washington, D.C.-based nonprofit.\nBut few of those suicide survivors get the follow-up care they need at a time when they are especially likely to attempt suicide again.\nIn other words, the intervention had nearly halved the risk of suicide in the six months after discharge.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two expert sources not involved with the study are cited, and we didn\u2019t detect any conflicts of interest that should have been disclosed.", "answer": 1}, {"article": "A colonoscopy isn\u2019t something you get just for giggles. Beyond the obvious unpleasantness, there\u2019s the small but real risk of complications that in rare cases can lead to hospitalization or even death.\n\nThat\u2019s why the American Cancer Society and other groups recommend that people screened for colorectal cancer using a colonoscopy wait a decade in between tests if no polyps or other signs of potential cancer are found. Polyps are slow-growing, and the benefits of being screened more frequently than that don\u2019t seem to outweigh the risks \u2026", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story used an American Cancer Society spokesman as an independent source.", "answer": 1}, {"article": "Learn more at www.genomedx.com and follow us on Twitter at Twitter @GenomeDx, Facebook, LinkedIn and YouTube.\nSAN DIEGO, July 14, 2015 /PRNewswire/ -- GenomeDx Biosciences today announced that a study featured on the cover of Urology demonstrates that Decipher\u00ae Prostate Cancer Classifier significantly influenced treatment recommendations following prostate surgery, reducing disagreement between urologists and radiation oncologists, and has the potential to enhance personalization of patient care.\n\"It is notable that while the Decipher test significantly influenced treatment decisions, it did not increase the total number of people receiving adjuvant therapy, suggesting that it helped ensure that the ones selected for adjuvant therapy are the ones most likely to benefit from it,\" said Doug Dolginow, M.D., chief executive officer of GenomeDx.\nThe study was designed to evaluate how the Decipher Prostate Cancer Classifier, which predicts the risk of metastasis after prostatectomy, would impact adjuvant treatment recommendations made by urologists and radiation oncologists.\nGenomeDx Biosciences is focused on transforming cancer patient care by putting usable genomic information in the hands of patients and their physicians.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "GenomeDx Biosciences funded the research. The company\u2019s name appears 14 times in the release and its product shows up 29 times.\nBut while the study itself makes detailed and explicit disclosures about funding and potential conflicts of interest (some of the researchers are employees of the company), the news release doesn\u2019t. That\u2019s unfortunate. Prostate cancer is very prevalent, Medicare can\u00a0cover the cost of a Decipher test, and about\u00a0half of men who get prostate cancer are covered by Medicare \u2014 so GenomeDx Biosciences has a lot to gain from more widespread use of its product.", "answer": 0}, {"article": "Side effects of dopamine agonists can include euphoria, hallucinations, weight loss, nausea, insomnia, tiredness or weakness, dizziness and drowsiness.\nThe report was published in the March 4 online issue of JAMA Internal Medicine.\nThe harms of medications may outweigh benefits for these individuals, Wilt said.\nThis is just a compilation of evidence that follows guidelines that have been long established in both Europe and the United States, Niethammer said.\nNonetheless, for people with moderate to severe restless legs syndrome symptoms, these medications provided important benefits, at least in the short term, Wilt said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes an outside expert who doesn\u2019t appear to have\u00a0any conflicts of interest related to this topic.", "answer": 1}, {"article": "The U.S. Centers for Disease Control and Prevention has more on cervical cancer screening.\nNot all experts agree, though, that current practice would change based on the study's findings alone.\nEinstein had a somewhat different take on the findings.\nThat decline has been largely attributed to widespread use of the Pap test.\n\"This shows that the strategy does work,\" he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes several sources who provide valuable perspectives.", "answer": 1}, {"article": "Those consuming higher doses saw some of the insulin resistance benefits and a drop in triglycerides, but not a significant increase in HDL.\nIn addition to Lin and Liu, the study's other authors are Isabel Zhang, Alina Li from Brown University, JoAnn Manson, Howard Sesso and Lu Wang from Brigham and Women's Hospital.\nCo-authors at Brigham and Women's also noted receiving funding from Mars Symbioscience, a research segment of Mars, Inc., which makes chocolate products.\nThe authors acknowledge funding from the National Institutes of Health including the National Heart, Lung and Blood Institute, the American Heart Association, and Pfizer.\n\"Our meta-analysis of RCTs characterizes how cocoa flavanols affect cardiometabolic biomarkers, providing guidance in designing large, definitive prevention trials against diabetes and cardiovascular disease in future work,\" said corresponding author Dr. Simin Liu, professor and director of the Center for Global Cardiometabolic Health at Brown University who worked with epidemiology graduate student and lead author Xiaochen Lin.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release makes the funding sources clear.\nIn addition to Lin and Liu, the study\u2019s other authors are Isabel Zhang, Alina Li from Brown University, JoAnn Manson, Howard Sesso and Lu Wang from Brigham and Women\u2019s Hospital.\nThe authors acknowledge funding from the National Institutes of Health including the National Heart, Lung and Blood Institute, the American Heart Association, and Pfizer. Co-authors at Brigham and Women\u2019s also noted receiving funding from Mars Symbioscience, a research segment of Mars, Inc., which makes chocolate products.", "answer": 1}, {"article": "Previous research has also suggested that fructans stimulate the growth of beneficial bacteria in the large intestine in a way that increases the body's absorption of minerals, including calcium and magnesium, which are needed for bone growth.\nThe National Osteoporosis Foundation has more about osteoporosis prevention.\nThe study was to be presented Tuesday at the national meeting of the American Chemical Society in San Francisco.\nThe fructans turn into alcohol when agave is processed into tequila, they said.\nBut drinking tequila won't help, the study authors noted.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources. ", "answer": 0}, {"article": "So, indeed, there has been a strong interest in giving the best additional therapy possible,\" Choti added.\nThe pool of nearly 1,100 patients that the researchers focused on were part of the large European Study Group for Pancreatic Cancer trial that took place across 159 pancreatic cancer centers located in Europe, Canada, Australasia and Japan.\nThe study authors noted that, currently, the prognosis for pancreatic cancer is very poor, with a five-year survival rate of less than 5 percent.\nAfter nearly three years of treatment, the researchers found almost no difference between survival rates in the two groups.\nThe finding, reported in the Sept. 8 issue of the Journal of the American Medical Association, stems from work conducted by Dr. John P. Neoptolemos, of the Cancer Research U.K. Liverpool Cancer Trials Unit at the University of Liverpool in England, and colleagues.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent source provides important big picture points about pancreatic cancer. More sources might have provided more context and filled in some of the holes.\nThe associations of the lead author and independent source were provided. The study authors themselves did not disclose any financial relationships.", "answer": 1}, {"article": "Trans fats, also called partially hydrogenated oils, enhance food texture and structure.\nHis study was published Wednesday in JAMA Cardiology.\nThe study hints at the potential for widespread health benefits from an upcoming nationwide ban, the authors and other experts say.\nThe results translate to 43 fewer heart attacks and strokes per 100,000 people, said lead author Dr. Eric Brandt, a Yale University cardiology fellow.\nDr. Mark Creager, former American Heart Association president, said the results echo previous studies \u201cand are consistent with the thinking of most scientists\u201d on potential benefits of these bans.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included two independent sources; we did not detect any undisclosed conflicts of interest.", "answer": 1}, {"article": "Ancient Greek and Chinese medical practitioners used a patient\u2019s scent to make diagnoses.\nThese molecules offer a whiff of who we are, revealing age, genetics, lifestyle, hometown \u2014 even metabolic processes that underlie our health.\nBut not every physician\u2019s nose is a precision instrument, and dogs, while adept at sniffing out cancer, get distracted.\nEach of us has a unique \u201codorprint\u201d made up of thousands of organic compounds.\nBlindfolded, would you know the smell of your mom, a lover or a co-worker?\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "All of the sources have a vested interest in seeing these technologies come to market. Someone without such interests might have provided a helpful brake on the story\u2019s enthusiasm.", "answer": 0}, {"article": "\"It was just advice,\" Jenkins said.\nTo put the diet to the real-world test, participants received a one-hour counseling session with a dietitian and an illustrated study booklet at the outset and, later, received a 30-40 minute follow up session.\nJenkins said participants achieved these results even though compliance to the whole grain, vegetarian diet was only about 40%.\nThe study was conducted from June 2007 to February 2009 at academic centers in Quebec City, Toronto, Winnipeg, and Vancouver.\nThe 351 participants in the study suffered from high cholesterol but were not on a cholesterol-lowering statin medication.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes the lead author of the study, but includes no truly independent\u00a0perspectives. It also does not disclose that many of the study authors have ties to organizations (e.g. Unilever) that might benefit from wider adoption of this diet.", "answer": 0}, {"article": "Kids with August birthdays are more likely to get an ADHD diagnosis.\nThe results for both techniques were very positive.\nThe results of one of those studies are out Tuesday in JAMA.\nIn an editorial, Madhav Goyal and Jennifer A. Haythornthwaite of the Johns Hopkins University School of Medicine said that the mechanisms for why meditation might work on back pain is still a mystery but that this question is merely \"academic\" for many clinicians and their patients who need immediate relief.\nThe two wrote that despite this and other unknowns, the study provides \"a compelling argument for ensuring that an evidence-based health care system should provide access to affordable mind-body therapies.\"\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Conflicts of interest don\u2019t appear to be an issue here, and the story includes\u00a0statements from\u00a0an accompanying editorial in JAMA, which was written by experts unaffiliated with the research. This squeaks by as Satisfactory, though it should be noted that most of this material was available via news releases (see below).", "answer": 1}, {"article": "Another approach to assessing the meaning of a PSA reading is to analyze how much antigen is traveling free in the blood and how much is bound to a companion protein, Dr. Scardino suggested.\nThe new guidelines will no longer rely on a single reading.\nPatrick Walsh\u2019s Guide to Surviving Prostate Cancer.\u201d\nAmong that 15 percent, Dr. Carter said, 15 percent had high-grade, potentially life-threatening cancers.\nHe explained that in men with an initially high level \u2014 say 10 or higher\u2014 velocity is not an issue.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Several sources are quoted.\u00a0 ", "answer": 1}, {"article": "The Raw Food diet and low-carb Atkins diet also scored poorly overall and ranked low in categories like \"Best Diets for Healthy Eating.\"\nWhen it comes to speedy weight loss, the HMR program and Biggest Loser diet shared the top ranking, followed by the Atkins diet in second place and Weight Watchers in third.\nThey also considered how easy each diet was to follow, as well as safety and nutritional value.\n\"Besides the rankings and data, each diet has a detailed profile that includes how it works, evidence that supports or refutes its claims and a nutritional snapshot -- tools that, along with the advice of a physician or nutritionist, can help consumers invest in diets that suit their lifestyles and further their health and wellness goals,\" Haupt said.\nThe MIND diet includes some features of the DASH diet and Mediterranean diet, such as high consumption of fruits, vegetables and fish, but focuses on foods that promote brain health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only source quoted is the editor of USN&WR and that comment is lifted directly from the news release. It\u2019s standard journalism practice to have at least one outside expert provide additional context or any opposing views in a news story. Many news organizations require two or three.", "answer": 0}, {"article": "A lot changed in between the births of my second and third daughters. For one thing, this time around I really am getting no sleep; for another, the pediatrician recommended something for our 1-month-old that is different from what had been suggested for our other children. She said we needed to pick up a liquid multivitamin that contains 400 international units (IUs) of vitamin D. It was a little confusing, because with our first daughter, now almost 4, the doctor told us to simply get her out in the sun from time to time to let her body produce vitamin D,...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The sources of information for this story were inadequate. \u00a0We learn the practice recommendations of one pediatrician (as reported by a parent) and a clinician who was reported to chair the Academy of Pediatrics nutrition committee. \u00a0There were no individuals with particular expertise in vitamin D who appeared to have been interviewed for this piece.", "answer": 0}, {"article": "If a woman's doctor tells her she does not need radiation after a mastectomy, the woman should be told why and she should ask if the radiation oncologist weighed in on the decision.\nEdge was co-chair of the panel that developed the new guidelines.\nThe guidelines don't offer a single formula for which patients need radiation therapy, Edge noted.\nAndrews said that one take-home message for patients is to expect the surgeon to have consulted with the radiation oncologist and others on her team.\nThe new guidelines help clarify what used to be a gray area, Andrews explained.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites two experts: One who was involved in crafting the guidelines, and one who was not. More input from independent sources would have made the story stronger, but this is sufficient to merit\u00a0a Satisfactory rating.", "answer": 1}, {"article": "The disease is characterized by an itching, oozing rash that can cover almost all of the skin.\nOn Saturday, the results of two large clinical trials of a new drug offered hope to the estimated 1.6 million adult Americans with an uncontrolled, moderate-to-severe form of the disease, atopic dermatitis, which is a type of eczema.\nThe constant itch, to say nothing of the disfigurement, can be so unbearable that many patients consider suicide.\n\u201cI knew immediately I was on the drug\u201d and not the placebo, said Daniela Velasco, an event planner in Playa del Carmen, Mexico.\nThere has never been a safe and effective treatment.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story fails to tell readers that every statistic and every expert quote is from sources funded by the companies, Sanofi and Regeneron, which are seeking approval to sell dupilumab. Not only were both trials funded by the companies, they largely controlled the writing of the New England Journal of Medicine article, to which the researchers \u201cprovided input\u201d and \u201cfinal approval\u201d of material produced with support from \u201cmedical writers who were paid by the sponsors.\u201d\nIn a startling omission, readers are not told that the lone \u201cindependent\u201d expert receives consulting and speaker fees from Regeneron. The story describes Dr. Mark Boguniewicz as \u201can atopic dermatitis expert at National Jewish Health and the University of Colorado School of Medicine who was not involved with the study.\u201d The story should have reported that Boguniewicz received more than $37,000 from Regeneron for consulting, speaking and travel reimbursements last year, according to Open Payments, a federal web site that collects reports of industry funding of physicians.", "answer": 0}, {"article": "Obstructive sleep apnea occurs when the soft tissues of the mouth and airway, especially the tongue, block air flow into the lungs.\nInspire is an invasive procedure, so it is not recommended as a first-line treatment and not everyone is a candidate.\nFor Kothare, the out-of-pocket expense for the device, the risks of surgery, plus the potential for the mechanism \u2014which moves the tongue forward \u2014 to break, doesn\u2019t make it a viable option for everyone.\nThe main side effect from the device is that people can wake up with a sore tongue.\nA clinical trial of Inspire therapy found a 78 percent reduction in the number of sleep apnea events per hour for patients.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not disclose that the one study it relies upon as evidence\u00a0for Inspire\u2019s effectiveness was funded by the drug company.", "answer": 0}, {"article": "\"Although we do not know why the men who took saunas more frequently had greater longevity (whether it is the time spent in the hot room, the relaxation time, the leisure of a life that allows for more relaxation time, or the camaraderie of the sauna), clearly time spent in the sauna is time well spent,\" Redberg wrote.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story references a written editorial published to accompany the story in JAMA, which we\u2019ll consider good enough for a satisfactory rating here. Actually interviewing someone not affiliated with the research might have yielded additional interesting insight on this topic.", "answer": 1}, {"article": "Probably not.\nBut the numbers came out this way: People who drink more than four cups of coffee each day have 39% lower odds of getting mouth or throat cancer, compared to people who don't drink coffee.\nBut whether these substances actually protect against cancer in humans is a question for future studies.\nThough there weren't enough data on decaf drinkers to draw conclusions, drinking tea -- even massive quantities -- was not protective.\nInterestingly, the protective effect of coffee was not diminished in drinkers and smokers.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent source was quoted.\u00a0 Someone could have commented on study methods.\u00a0 Someone could have commented on the context of all of the other coffee-cancer studies that have been done.\u00a0 Someone should have been interviewed for such perspective, but it doesn\u2019t appear that anyone was \u2013 at least no such interviews appear in the story. We don\u2019t like single-source stories in any form of journalism, least of all in health/medical stories. ", "answer": 0}, {"article": "You've seen high-definition televisions. Now some medical centers are marketing their high-definitioncolonoscopes, which they say will detect more pre-cancerous polyps. Several recent studies have found a small benefit to high-definition colonoscopy over the standard variety, but gastroenterologists say physician technique is more important in detecting polyps than equipment.\n\nColonoscopy, a screening test doctors recommend for most people starting at age 50, allows doctors to remove pre-cancerous growths before they become...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Great job in identifying and calling out conflicts. There is one independent source in the story and more would have been nice. At the same time, though, the reporter pulled together so much good, well balanced information that the independent voices were not as missed as they often are in stories like this.", "answer": 1}, {"article": "\"We have no right as parents or as physicians or adults to strap them down and chop off a normal part of their body.\nSome think the academy's position is long overdue, and that the group should have gone even further and more forcefully recommended circumcision.\nThey liken the procedure to female genital mutilation.\nChapin and other critics argue that the scientific evidence is questionable.\n\"There is clear evidence that supports the health benefits of circumcision,\" said Susan Blank, who led the 14-member task force that formulated the new policy being published in the journal Pediatrics.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Both advocates for circumcision and opponents were quoted within the story.", "answer": 1}, {"article": "More than 300 million people worldwide have depression, according to the World Health Organization, of which less than half recieve effective treatments.\n\u201cAlthough antidepressants are of proven benefit\u2014as this study shows,\u201d she said, \u201cno doctor wants their patients to become reliant on medication.\u201d\n\nCarmine Pariante, a professor at the UK\u2019s Institute of Psychiatry, Psychology and Neuroscience and spokesperson for the Royal College of Psychiatrists, said the study \"finally puts to bed the controversy on antidepressants.\"\nIn the U.K, where a number of the study authors are based, at least one million more people could benefit from drugs or psychotherapy, senior author John Geddes said.\nThe study results represent the most comprehensive evidence currently available, they wrote.\nThe results add up to a complex treatment picture for what authors called \u201cone of the most common, burdensome, and costly psychiatric disorders worldwide in adults.\u201d\n\nAntidepressants do not improve symptoms in about 40 percent of people, study author Andrea Cipriani of Oxford University told a press briefing.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides quotes from three psychiatrists who were not authors on the study, taken from an online source called Science Media Centre.\nIt doesn\u2019t say that one of them \u2014 Carmine Pariante \u2014 disclosed he received research funding from companies that make antidepressants. Pariante\u2019s quote seems to have provided the basis for the story\u2019s lead, which stated antidepressants \u201creally do work.\u201d", "answer": 0}, {"article": "DOI: 10.1001/jamacardio.2016.4828\n\nCONTACT: For more information or to schedule an interview, please contact the NHLBI Office of Science Policy, Engagement, Education, and Communications at 301-496-5449 or nhlbi_news@nhlbi.nih.gov (link sends e-mail)\n\nPart of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders.\nHowever, a randomized study is needed to confirm these findings, according to the authors.\nWHO: Jerome Fleg, MD and Yves Rosenberg, MD, M.P.H., Division of Cardiovascular Sciences, NHLBI, NIH, are available to comment on the findings and implications of this research.\nThe study, funded by the National Heart, Lung, and Blood Institute (NHLBI), appears in the December 28 issue of JAMA Cardiology.\nNHLBI press releases and other materials are available online at http://www.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release makes the funding sources for the study clear.", "answer": 1}, {"article": "[Watch how the body\u2019s \u2018serial killers\u2019 stalk and attack cancer cells]\n\n\"This is a first in class agent, a brand new therapy,\" Harrington said.\nWhen the latest trial was started, Harrington explained, there was no standard of treatment for melanoma -- so it's compared to a treatment that no one expected to outpace T-VEC.\nNow that other therapies -- ones that target specific mutations in patients' cancer cells -- are showing more success than what was available when the trial was formed, researchers will have to see how T-VEC compares.\nThe results of the trial were published Tuesday in Journal of Clinical Oncology.\nBut this is the first time a modified virus has been successful in carrying out that treatment.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Nearly every author on this paper has some association with Amgen, which is disclosed in the paper, but the blog post makes no mention of these affiliations. Only one person is quoted and he is one of the authors of the paper. This story needed the evaluation and comment of someone not involved with the phase III study. Such an unaffiliated expert would have made clear that it is uncertain when this agent should be used compared to other melanoma therapies.", "answer": 0}, {"article": "AMG145, along with other PCSK9 inhibitors being developed by companies like Pfizer, Regeneron Pharmaceuticals Inc in partnership with Sanofi and Roche, is a man-made antibody.\nThe most common side effects seen in the trial were injection-site reactions, cold-like symptoms and headache.\nThe trial, presented here at the annual scientific meeting of the American Heart Association, included 168 patients with heterozygous familial hypercholesterolemia, in which a defective gene inherited from one parent impairs the ability to properly metabolize LDL.\nThe new drug, given by injection every four weeks, is part of a promising new class of biotech medicines known as PCSK9 inhibitors designed to target a protein that prevents the body from removing artery blocking LDL cholesterol from the bloodstream.\nLOS ANGELES (Reuters) - Amgen Inc\u2019s experimental drug AMG145 reduced levels of bad cholesterol by as much as 55 percent in combination with statin drugs in patients genetically predisposed to high cholesterol, according to data from a midstage trial presented on Monday.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Not only are independent voices absent from this story, there is no mention that the study was funded by Amgen and the researchers were either company employees or receive consulting fees or other compensation from Amgen.", "answer": 0}, {"article": "Dozens of biotechnology and pharmaceutical companies including Alnylam, Merck, Pfizer, Novartis and Roche are looking for ways to manipulate RNA to block genes that make disease-causing proteins involved in cancer, blindness or AIDS.\nNor could he say if there were any safety concerns.\nBut getting the treatment to the right target in the body has presented a challenge.\nDavis could not say whether the therapy helped shrink tumors in the patients, but one patient did get a second cycle of treatment, suggesting it might be.\nDavis said that part of the study will be presented at the American Society of Clinical Oncology meeting in June.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources interviewed in the story. ", "answer": 0}, {"article": "And tobacco kills one in 10 people worldwide, according to the World Health Organization.\nOther treatments, such as nicotine patches and gum, can also help some smokers cut back gradually, she said.\n\u201cThis allows us to reach a much broader population of smokers who aren\u2019t willing to quit abruptly or set a quit date, and it shows that people can quit without going cold turkey,\u201d said lead study author Dr. Jon Ebbert, a professor in primary care and internal medicine at the Mayo Clinic in Rochester, Minnesota.\n\u201cIt offers compelling evidence that gradual reduction should be considered to facilitate quitting,\u201d she said.\nTo see if Chantix, which is manufactured by Pfizer, could help smokers quit without going cold turkey, Ebbert and colleagues randomly assigned 1,510 people at 61 centers in 10 countries to receive either the drug or a placebo for 24 weeks.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story notes that Chantix is made by Pfizer \u2014 but does not tell readers that Pfizer funded the study. Also, the story quotes two experts. One is an author of the study. The other is Dr. Caryn Lerman of Penn\u2019s Abramson Cancer Center. According to declarations in her published work, Lerman has served as a consultant/advisor to Pfizer regarding medications for nicotine dependence. The story would have benefited from including an expert without (real or perceived) ties to Pfizer.", "answer": 0}, {"article": "ASDs mainly affect a person\u2019s social interaction and communication, with symptoms that can include speech disturbances, repetitive and/or compulsive behaviour, hyperactivity, anxiety, and difficulty adapting to new environments.\nWe hope the tests will also reveal new causative factors.\nThe outcome was a diagnostic test better than any existing method.\nAt this stage, the results presented are not strong enough to suggest that this method could be used for the diagnosis of autism.\nHowever, researchers believe their new tests could reveal yet-to-be-identified causes of ASD.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no independent sources. Including independent experts could have given the story much-needed context, including whether there are other studies looking for potential biomarkers for ASD.\nConflicts of interest are not mentioned, and we could find none.", "answer": 0}, {"article": "\"We try to time the pattern to stimulation so that it's integrated with their ability.\nDue to his improvements, the research team is developing a system that McGlynn can use at home and outside.\nA video of him walking with and without the system can be found at: https:/ .\nA video of him walking with and without aid of the system can be found here: https:/ .\nThe researchers are seeking funding to fit him with a permanent FES system in a clinical trial.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t note the funders but they are listed on the sidebar of EurekAlert!, a host site for the news release.", "answer": 1}, {"article": "\"So, we tested it against viruses that came from the 1930s until the current ones, and it kills all of the H1s.\nGregory Chinchar, a professor in the University of Mississippi Medical Center's department of microbiology and immunology, said that he was surprised that the peptide targeted the hemagglutinin on the flu virus.\n\"We have identified a potentially new treatment for H1N1 human influenza virus, which is a peptide that comes from the skin of a frog from southern India,\" said Joshy Jacob , an associate professor in the Emory University School of Medicine's microbiology and immunology department, who led the study.\nThe urumin peptide could be a novel treatment since it targets the hemagglutinin, unlike current drugs on the market which target other parts of the virus, resulting in less impact, Jacob said.\n\"The peptide described in the Immunity report is somewhat unusual because of the apparent specificity,\" Rollins-Smith said about how urumin specifically targets H1 viruses.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The primary source is clearly linked to the study, and two other sources are identified as independent of the research. Although the story does not mention funding sources, a news\u00a0release describing the research indicates that funding came from the university itself, not from external sources.", "answer": 1}, {"article": "The way it works: A doctor draws a vial of your blood and separates it into its key components, the red blood cells, the clear serum and the platelets. The physician then adds vitamins and amino acids to the mix, and the enriched serum is injected into your face.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No independent sources; no evidence of any independent reporting.\u00a0 ", "answer": 0}, {"article": "Asthma on the Rise in U.S.\nThere's much room for improvement, Shimoide says.\nYoshiteru Shimoide, MD, head of the Yoshiteru Shimoide Clinic of Internal Medicine in Kagoshima City, Japan, presented the results here at the annual meeting of the American Academy of Allergy, Asthma, & Immunology (AAAAI).\nThe study did not look at possible side effects of kampo herbs.\nHerbs used in the current study include Scutellaria root, Coptis rhizome, gardenia fruit, hoelen, cinnamon bark, and Glycyrrhiza (aka licorice) root.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "One independent expert was quoted, adding important cautious perspective.", "answer": 1}, {"article": "Rather, surgeons move electronic instruments that are linked to the movement of other instruments inside the body, while they watch a three-dimensional image of what\u2019s going on inside.\n\u201cWe were surprised that (surgery with the robot) did not have better outcomes than (the surgeon alone), as we have always believed if you can see more and see better you can do more and do better,\u201d the authors write.\nIn this case, the robot could turn what would have to be an open surgery into a simpler one.\nThere was no difference in how much blood patients lost, and there were no complications in either group.\nUsing a robot for basic surgery, like the kind studied here, would be like using a computer to do addition, he told Reuters Health.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As noted above, the comments from Falcone were essential. It might have been worth noting that both the hospitals mentioned in the story actually promote robotic surgery for endometriosis quite heavily. Here\u2019s one example:http://www2.northside.com/RoboticSurgery/Robotic-Surgery-At-Northside/Gynecologic-Surgeries/Robotic-Endometriosis.aspx", "answer": 1}, {"article": "Only children with moderate cough and severe stuffy nose were eligible, and those were divided into three groups.\nShu says when used properly, Vicks appears to be safe.\nThe next day parents were questioned about their child's symptoms overnight.\nChildren in all three groups got better, but those treated with the VapoRub saw the greatest improvement, and parents in this group also had improved sleep, the study found.\nIn the study, funded by an unrestricted research grant from Procter & Gamble, makers of Vicks, researchers took 138 children between the ages of 2 and 11, with symptoms like cough, congestion, runny nose and restless sleep that lasted seven days or more.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThe story does include a comment from an independent pediatrician, and the story notes that she works for CNN. It also points out that funding for the trial came from the company that sells VapoRub and that the lead researcher is an advisor to the company.", "answer": 1}, {"article": "Viagra is one of three licensed drugs to treat erectile dysfunction, Davies explained. The other two are Cialis and Levitra. They can take from half an hour to several hours to work, and they're not for everyone: Men who've had a stroke or heart attack are told to use the drugs with caution, reports the Daily Mail. Even those without medical issues simply don't like the wait.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The lead researcher of this rat study was interviewed. And a urologist was quoted briefly \u2013 but only about the potential of the idea. \nNo independent expert opinion appeared to evaluate the research and to judge the story\u2019s claims that this animal study \"promises instant anti-impotence with no side effects.\" ", "answer": 0}, {"article": "Moffitt is the No.\nThe study was supported by funds received from the American Cancer Society and the DeBartolo Family Personalized Medicine Institute Pilot Research Awards in Personalized Medicine.\nThey included female patients in the analysis who were diagnosed between 1973 and 2011 with early-stage breast cancer.\nThe researchers found that delaying surgery due to neoadjuvant radiation therapy was not a detriment to survival.\nFor more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter and YouTube.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources were noted and do not appear to be a conflict of interest.", "answer": 1}, {"article": "\"We're always searching for simpler things to do,\" Brooks said.\nThe findings, reported online Dec. 5 in the British Journal of Surgery, sound good.\nNow, a small pilot study suggests such a test could be developed.\nBrooks said it would be nice to have a very simple, accurate screening test -- whether that means a breath test or blood or urine tests.\nAltomare's team acknowledges that there is a lot of work left to do.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "An expert from the American Cancer Society\u00a0provides much-needed context and perspective on this research.", "answer": 1}, {"article": "Dr Sheraz Markar, an NIHR Clinical Trials Fellow from Imperial College London, under the supervision of Professor George Hanna, told the Congress: \"At present the only way to diagnose oesophageal cancer or stomach cancer is with endoscopy.\nThe results showed that the test was 85% accurate overall, with a sensitivity of 80% and a specificity of 81%.\nIn the new study, the research team collected breath samples from 335 people at St Mary's Hospital, Imperial College Healthcare NHS Trust; University College London Hospital; and the Royal Marsden Hospital, London.\nThe new research, involving more than 300 patients, showed that the test could diagnose cancer with an overall accuracy of 85%.\nResearchers measured the levels of the five chemicals in each sample to see which ones matched to the 'chemical signature' that indicated cancer.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funders are named in a sidebar to the release on the EurekAlert! website. Ideally, the funders would also be listed in the release text so that when the release is republished that information is available.\nThe study abstract noted that the researchers stated they had no conflicts to declare.", "answer": 1}, {"article": "For more information, visit www.camurus.com.\n\"Importantly, the fact that CAM2038 will be given in the clinic by health providers should address concerns about diversion of buprenorphine for illicit use.\n\"The current study demonstrated that weekly injections of CAM2038 produced significant and robust opioid blockade, a critical mechanism of efficacy for medications treating opioid dependence.\n\"The results also confirm the dose selection in the current Phase 3 program and the potential of CAM2038 as a future treatment alternative for patients with opioid use disorder, from initiation to long-term maintenance.\"\n\"The study results show that CAM2038 provides rapid and extended blockade of opioid effects,\" said Fredrik Tiberg, President and CEO of Camurus.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "No mention is made of funding, and the roles of the two academics quoted are never made clear. We are not told whether they helped carry out the study itself, whether they have a financial interest in the product, or whether they are speaking as disinterested expert observers.\nAccording to a speakers bio for a conference on treating opioid addiction, one of the experts quoted has financial ties to the sponsors of the drug tested. This conflict of interest should have been mentioned in the release.", "answer": 0}, {"article": "Milo A. Puhan, MD, is director of the Epidemiology, Biostatistics and Prevention Institute and professor of epidemiology and public health at the University of Zurich.\nThat\u2019s the final recommendation from the US Preventive Services Task Force (USPSTF) after more than a year of study and lively public comment.\nIf there was a foolproof way to identify individuals at high risk for a future heart attack or stroke, as well as those at high risk for developing complications, we would know who should be taking aspirin for primary prevention and who should not.\nVerheugt: Even doctors are confused\n\nBy Kirsten Bibbins-Domingo: Taking aspirin is easy, but deciding whether or not to take aspirin for prevention is complex.\nWith an international team of colleagues, we created an online tool that calculates whether the benefits of aspirin for primary prevention (preventing heart attack, ischemic stroke, and cancer) are greater than the harms (severe hemorrhagic stroke and severe gastrointestinal bleeds).\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We applaud the breadth of sourcing in this piece. Readers are told that Kirsten Bibbins-Domingo, is the\u00a0vice-chair of the US Preventive Services Task Force, and she weighs in with her assessment. \u00a0Other physicians, however, seem independent of the USPSTF and are unlikely to be financially conflicted with the manufacturers of aspirin.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/15/national/a141001S34.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "", "answer": 1}, {"article": "Cognitive scientists use this opportunity, with patients\u2019 consent, to present memory tests and take recordings.\nShe agreed to the memory testing for the study.\n\u201cI would remember one or two items from a list of objects in a kitchen, for instance, then think, \u2018Oh no, what else was there?\u2019 \u201d\nAll the while, the scientists monitored a handful of \u201chot spots\u201d in the brain which, previous work had shown, were strongly related to memory encoding.\nThe preoperative \u201cevaluation\u201d is a fishing expedition of sorts, in which doctors sink an array of electrodes through the top of the skull and wait for a seizure to occur, to see whether it\u2019s operable.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The end of the scientific article that this story was based on notes that the two\u00a0senior authors are forming a company \u201cto develop and commercialize brain stimulation therapies for memory restoration.\u201d This should have been included in the story.", "answer": 0}, {"article": "But it\u2019s not proof,\u201d Broderick said.\nWe wanted the superiority of endovascular treatment.\u201d\n\nWhether the findings will cause physicians to abandon the practice is uncertain.\nThe three studies reported this week (which will eventually be published in the New England Journal of Medicine) tested the hypothesis in a rigorous way.\nWhy endovascular treatment wasn\u2019t better is a mystery that the researchers are struggling to explain.\nThe results of the clinical trials, presented this week at a meeting in Hawaii, shocked and surprised stroke physicians.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The\u00a0deputy director of the National Institute of Neurological Disorders and Stroke provided some perspective, plus the reporter worked to include statements from investigators from each of the three trials and we credit that effort as satisfactory.", "answer": 1}, {"article": "THE AMERICAN SOCIETY OF ANESTHESIOLOGISTSFounded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 52,000 members organized to raise and maintain the standards of the medical practice of anesthesiology.\n\u201cLabor pain matters more than just for the birth experience.\nResearchers found the higher the PIP scores, the lower the EPDS scores.\nLike ASA on Facebook, follow ASALifeline on Twitter and use the hashtag #ANES16.\nIt may be psychologically harmful for some women and play a significant role in the development of postpartum depression,\u201d said Grace Lim, M.D., director of obstetric anesthesiology at Magee Women\u2019s Hospital of the University of Pittsburgh Medical Center and lead investigator on the study.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t mention who funded the study.", "answer": 0}, {"article": "A total of 117 clusters (or \"rings\") were identified, each made up of an average of 80 people.\n\"This both historical and innovative trial was made possible thanks to exemplary international collaboration and coordination, the contribution of many experts worldwide, and strong local involvement,\" said Dr John-Arne R\u00f8ttingen, Specialist Director at the Norwegian Institute of Public Health, and the chairman of the study steering group [4].\nThe vaccine is the first to prevent infection from one of the most lethal known pathogens, and the findings add weight to early trial results published last year.\nMerck has also submitted the vaccine to WHO's Emergency Use and Assessment Listing procedure, a mechanism through which experimental vaccines, medicines and diagnostics can be made available for use prior to formal licensure.\nAfter interim results were published showing the vaccine's efficacy, all rings were offered the vaccine immediately and the trial was also opened to children older than 6 years.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release identifies the funding sources for the study, which included WHO and a number of government agencies from Canada, the United Kingdom, Norway, along with the international organizations the Wellcome Trust and M\u00e9decins Sans Fronti\u00e8res. The news release also identifies the organizations with which the study\u2019s research team members were associated, although it does not give any indication of the extent to which research team members or their organizations receive additional funding from Merck, which obviously stands to gain the most if the vaccine proves effective and is recommended for use by the World Health Organization.", "answer": 1}, {"article": "\u201cThis is a first step,\u201d he said, \u201cand all these applications will require further work.\u201d But, he added, if the testing is successful, \u201cI think it will be very popular.\u201d\n\nThe idea for second skin originated more than a decade ago when Dr. R. Rox Anderson, a professor of dermatology at Harvard Medical School, was approached by Living Proof, which had been working on a polymer to be used as a hair product.\nOne of the first applications, said Dr. Barbara A. Gilchrest, a dermatology professor who is part of the research team, was on undereye bags, a condition that plagues so many middle-aged and older people.\nand a scientific founder of Living Proof, started searching for something that would work.\nSince dermatologists also know about hair, the company consulted him.\n\u201cWe were looking for safety, spreadability, adherence, and the right kind of mechanical and optical properties.\u201d\n\nThe \u201cskin\u201d can last for more than a day.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly uses sources beyond those provided by the news release. It also gets applause for pointing out clearly the connection between the researchers and the companies licensing the product saying, \u201cAll of the authors on the new paper have an equity interest in Living Proof and so, indirectly, in Olivo,\u201d (the two identified companies).\u00a0 NBC\u2019s story on the same research\u00a0didn\u2019t\u00a0make this financial connection nearly as clear.", "answer": 1}, {"article": "Michael T. Lotze, a professor of surgery and bioengineering at the University of Pittsburgh, said that \"the work is heroic.\nResponse by others in the field was positive but not effusive.\nThe report, published online by the journal Science, is the latest result of a three-decade effort by surgeon Steven A. Rosenberg to find ways to manipulate the human immune system to fight cancer.\nThe new report, however, is believed to be the first time that genetically engineered immune system cells -- specifically, T lymphocytes -- have produced the same effect.\nWhile the good results in two patients are encouraging, \"in terms of response rates, the overwhelming data is that T cells, even in high numbers, are inadequate to mediate sufficient anti-tumor effects,\" Lotze said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This article included helpful comments from clinicians familiar with the experimental approach but who were not directly involved with this particular study. They help to temper the enthusiasm of the principal investigator on this project and to balance the piece.", "answer": 1}, {"article": "Prostate cancer is very common, showing up in 240,000 U.S. men every year.\n\u201cOur findings with Western diet and prostate cancer-specific mortality, however, were surprising, in part because there are very little data regarding how diet after diagnosis may impact disease prognosis.\u201d\n\nThe findings could be important for many men.\nProstate cancer survivors who eat a typical American diet loaded with red meat, cheese and white bread are far more likely to see their cancer come back and kill them, and they\u2019re more likely to die sooner of any disease than patients who eat a healthier diet, researchers reported Monday.\n\u201cOur results suggest that the same dietary recommendations that are made to the general population primarily for the prevention of cardiovascular disease may also decrease the risk of dying from prostate cancer among men initially diagnosed with nonmetastatic disease (cancer that has not spread),\u201d said Dr. Jorge Chavarro of Brigham and Women\u2019s Hospital and Harvard Medical School, who led the study.\nSo-called Mediterranean-style diets, with plenty of fresh vegetables and fruit, olive oil instead of saturated fat, whole grains and more fish than meat, ward off these same diseases.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "News articles always come out stronger when sources other than those with a stake in a study\u2019s findings are sought out and quoted. In this case, an additional comment from a nutritional epidemiologist not involved in this study would have provided context.", "answer": 0}, {"article": "Several studies have found that dark chocolate, with its heart-healthy flavonols, can lower blood pressure and improve cholesterol.\nThe study is published in the journal BMJ.\nThey did not study actual people eating actual chocolate.\nMaybe, according to a new study from Australia.\nThey found it would be.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The Harvard nutritionist/epidemiologist provided vital perspectives.\n\u00a0", "answer": 1}, {"article": "(Sunlight stimulates production of vitamin D for people in sunnier climes.)\nThis practice isn't totally harmless.\n\"I think there's been a disconnect between the observational studies and the randomized clinical trials to date,\" Manson said.\nI think there's a general perception that if some is good, more is better.\nBut somehow we've arrived at a point when some physicians are prescribing large doses of Vitamin D supplements for their patients in the hope of preventing cancer, cardiovascular disease, diabetes, autoimmune disorders and other maladies, despite a lack of evidence that this works, according to a new commentary in the Journal of the American Medical Association.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites only two sources: Dr. Manson and the\u00a0JAMA commentary co-authored by Manson. While Dr. Manson would normally qualify as an independent expert source in any story on vitamin D, here she\u2019s basically being asked to comment on an article that she wrote which is the basis for the story. The story would have been much stronger if it had also included input from someone who didn\u2019t author the JAMA commentary.", "answer": 0}, {"article": "\"These are very basic facts, concerning simply who lived and died,\" he noted.\nDr. Eric N. Prystowsky, cardiologist and director of clinical electrophysiology at St. Vincent Medical Center in Indianapolis, said that the findings are \"good news,\" but cautioned against over-interpreting the data.\nBut, Prystowsky continued, \"this analysis does show two impressive things: one, that patients who are not super-selected for a trial do well with these devices from a mortality standpoint; and two, that patients who had home-monitoring had better outcomes.\"\nThe study authors noted that the observation is somewhat surprising, given that some of the patients not enrolled in structured studies have already experienced a cardiac event and are therefore prescribed such devices to prevent a recurrence.\nTUESDAY, Nov. 23, 2010 (HealthDay News) -- Implantable devices designed to control heart rhythm and efficiency while preventing sudden death among heart failure patients are as effective at ensuring patient survival in real-world situations as they are in controlled study environments, new research suggests.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does use one independent source, but it fails in another way. It does not point out that the study was funded by the device maker Boston Scientific. Also,\u00a0Dr. Prystowsky notes funding support from Boston Scientific (http://www.theheart.org/article/1050051.do ), but this is not acknowledged.", "answer": 0}, {"article": "WASHINGTON -- A U.S. Food and Drug Administration panel of outside medical experts backed a Novartis AG drug, Exelon, for treatment of dementia in patients with Parkinson's disease.\n\nExelon is currently on the market to treat mild to moderate Alzheimer's disease. The FDA said it wasn't sure whether dementia associated with Parkinson's was much different than dementia associated with Alzheimer's. Dementia is a condition that typically first presents itself as memory loss greater than what would be expected as part of the normal...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not provide any independent input about the therapeutic claims of rivastigmine for treating dementia in people with Parkinson\u2019s. ", "answer": 0}, {"article": "\u201cAnd you need all hands on deck.\u201d\nAlkermes spokeswoman Jennifer Snyder said the company\u2019s sales team helps educate corrections staff and community care providers only after they have shown interest in Vivitrol.\nDr. Joshua Lee, of New York University\u2019s medical school, said more evidence is needed to determine whether the medication can help substantial numbers of people and whether it\u2019s worth paying for, but the early results are encouraging.\nThe results, published in March in the New England Journal of Medicine, have been promoted by the drugmaker, Ireland-based Alkermes, as it markets Vivitrol to U.S. correctional systems.\nThe evidence for giving Vivitrol to inmates is thin but promising.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The company that owns Vivitrol is clearly identified, as are a couple of sources who are studying the drug, including the first author of the NEJM study. At least one source, who expresses concern about the company\u2019s vigorous marketing to prisons, appears to be independent. The National Institute on Drug Abuse, which supported the research discussed in the NEJM article, is also identified.", "answer": 1}, {"article": "The main campus also includes University Hospitals Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; University Hospitals MacDonald Women's Hospital, Ohio's only hospital for women; and University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center.\n\"These survey results show that something as simple as a change to a more elegant delivery system that is easier to use and not messy might empower more post-menopausal women to seek prescription treatment for VVA, and perhaps help them stay with the application guidelines for longer,\" said study first author Sheryl Kingsberg, PhD, Division Chief, OB/GYN Behavioral Medicine, UH Cleveland Medical Center; Professor of Obstetrics and Gynecology and Psychiatry, Case Western Reserve University School of Medicine; and first author of the survey analysis.\nThe new results were part of a multi-center randomized, placebo-controlled phase 3 clinical trial for TX004HR, an investigational bio-identical 17\u03b2-estradiol applicator free vaginal softgel capsule.\nFinancial disclosure: Dr. Kingsberg has served as a consultant for TherapeuticsMD, the manufacturer of TX004HR, as well as Acerus Pharmaceuticals, AMAG Pharmaceuticals, Bayer Healthcare, Emotional Brain, Materna, Novo Nordisk, Nuelle, Palatin Technologies, Pfizer, Sermonix Pharmaceuticals, Shionogi Inc. and Valeant Pharmaceuticals.\nThe survey, which included 731 respondents with a 96 percent response rate, sought to quantify participants' satisfaction with the application method and overall treatment delivery system.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release notes that Dr. Sheryl Kingsberg, the study\u2019s first author, has been a consultant for TherapeuticsMD, which manufactures the active ingredient in the softgels, and for a number of other pharmaceutical companies. It did not mention that several of the study\u2019s other authors also have received research support or consulting fees from TherepauticsMD.\nThis study carries a strong imprint of its funder, the manufacturer. The acknowledgement in the study notes that even the authorship of the paper was contracted out to a professional medical writing firm, which is a practice that is often criticized. The journal manuscript acknowledged it; the news release could have as well.", "answer": 0}, {"article": "A complex and expensive pacemaker-defibrillator can significantly improve the chance for survival among the tens of thousands of heart-failure patients with only mild symptoms, according to a major, multiyear clinical study.\n\nThe research, regarded as likely to change medical practice, showed that the device to \"resynchronize\" the hearts of such patients lowered the death rate by 29% in such patients over 40 months, compared to those who had a standard defibrillator implanted.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does a good job quoting outside sources, but we wish it had done a better job identifying how many of these folks have conflicts.", "answer": 1}, {"article": "They found that compared with the placebo, there was a 27% reduced risk of coronary heart disease, a 28% reduced risk of dying from coronary heart disease, and a 25% reduced risk of coronary \u201cevents\u201d such as a heart attack.\nAll the men had very high levels of LDL, or \u201cbad\u201d cholesterol, (higher than 4.9mmol/L) but had no evidence of heart disease at the start of the study.\n\u201cOur analysis firmly establishes that controlling LDL over time translates to fewer deaths in this population.\u201d\n\nProfessor Sir Nilesh Samani, medical director at the British Heart Foundation, said: \u201cThis research further demonstrates the benefits of statins for people who have high levels of cholesterol in their blood.\nThe 20-year project examined data from 2,560 men taking part in a randomised clinical trial to test the effects of statins versus a placebo.\nResearchers from Imperial College London and the University of Glasgow found impressive results among those on statins, who were given the widely-prescribed type pravastatin.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story doesn\u2019t note how the study was funded through Sanofi, a company that makes, markets, and sells statins, Furthermore, most of the authors disclosed that they have accepted either grant money or fees from major pharmaceutical companies. In fact, five out of the the eight authors had or have a financial relationship with Sanofi.", "answer": 0}, {"article": "\"It's been a miracle to me,\" Wolfe said.\nThe study, published in today's Journal of the American Medical Association, was funded by the maker of the drug, Johnson & Johnson Inc.'s Ortho-McNeil Neurologics.\nIt's unclear whether the findings will make a dent in an addiction that affects millions of Americans.\nThe drug costs at least $350 a month, plus the price of doctor's visits.\nAll volunteers were encouraged \u2014 but not required \u2014 to stop drinking.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Experts in the field who were not associated with this study were quoted in the story.\u00a0 In addition, the story clearly indicated that the study was funded by the maker of the drug.", "answer": 1}, {"article": "A female testosterone patch showed promise at boosting older women's enjoyment of sex, but concerns about the cancer risk of hormone therapies mean U.S. women won't be getting an equivalent of Viagra anytime soon.\n\nProcter & Gamble Co., the Cincinnati consumer-products giant, has worked since 1999 to secure U.S. approval for its Intrinsa patch, intended to increase sex drive and satisfaction in women after menopause.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The only sources contacted for this story are representatives of two companies involved with development of female sexual satisfaction products, including the one studied in the journal report. \nThe viewpoints of independent clincians and researchers would have been valuable.\u00a0 ", "answer": 0}, {"article": "\u201cIt\u2019s not one size fits all.\u201d\n\nBut national guidelines still recommend that adults over age 65 follow the same guidelines as younger people: to get at least 150 minutes of moderate-to-vigorous physical activity per week.\nLaCroix says her new study refutes that research and shows that older adults can still benefit at levels below the moderate-to-vigorous guidelines.\nQuestionnaires used in self-reported studies don\u2019t do a good job of encompassing all the ways people get physical activity throughout the day, she says, which may have skewed previous study results.\nActivities like these account for more than 55% of older adults\u2019 daily activity, says LaCroix, so the fact that they were protective in this study is very good news.\nThe researchers hope their work sparks more discussion about how people\u2014especially older ones\u2014think about exercise and their goals for being active.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "No outside sources are cited in the story, nor does the story make clear who funded the research (addressing potential conflicts of interest).", "answer": 0}, {"article": "It is high in polyphenols--compounds with strong antioxidant activity that in test-tube and animal models show anticancer and heart-protective effects.\nGood clinical studies are few, however, and although I and other physicians tell our patients to drink green tea, there hasn't been any definitive proof of the value of that advice.\nThere's a growing body of research to suggest that both are probably good for you.\nThat's why I was so interested in a report last week in the Journal of the American...\nWe've heard a lot about the health benefits of tea, especially green tea.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There are no quotes from any investigators in the field. Even if Dr. Weil\u2019s expertise is taken into account as author of the piece, that is still only a single-source perspective. ", "answer": 0}, {"article": "Researchers are developing decision aids to guide physicians and consumers beginning to struggle with lung cancer screening.\nBut it is worth remembering that however effective it is, screening can\u2019t ward off disease.\nSo those required \u201cshared decision-making visits\u201d with doctors will involve lots of very individual questions and judgments.\nThe post-surgical death rate in the national trial was just 1 percent, but that involved major medical centers with specialized radiologists and surgeons \u2014 the ideal setting.\nResearchers call it \u201ccompeting mortality.\u201d Finding lung cancer is a hollow victory if patients endure testing and treatment, then die of another illness before the cancer would have killed them.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The sources in this story are clearly identified, but no effort is made to articulate the presence\u2014or absence\u2014of conflicts of interest. However, a quick search of these individuals does not reveal any major conflicts, so we\u2019ll rule this Satisfactory.", "answer": 1}, {"article": "\u201cLet\u2019s talk about your test results,\u201d my neurologist said.\n\nShe looked as if she had good news. Instead, it was shocking.\n\nThe carotid artery on the left side of my neck, one of the brain\u2019s two main sources of blood and oxygen, was clogged with fatty plaque, the doctor said. The artery was almost completely blocked.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "It is an inherent weakness of this sort of first-person reporting that there is an absence of independent sources. All but one of the physicians quoted in the story were personally involved in the reporter\u2019s case. The one exception is a vascular surgeon who strongly advocates for broader carotid artery screening. There are no quotes from experts who were members of the task force that recommended against widespread screening.", "answer": 0}, {"article": "Depression presents an enormous disease burden, with a reported 350 million people worldwide suffering from the disease, but traditional SSRI treatments carry a burden of their own - in dollars and side effects.\nThe study team found that in 112 participants with analyzable data, consumption of magnesium chloride for six weeks resulted in a clinically significant improvement in measures of depression and anxiety symptoms.\nThe study participants, who were currently experiencing mild-to-moderate depression, had a mean age of 52, with 38 percent of them male.\nTheir results showed that magnesium is safe and effective and comparable to prescription SSRI treatments in effectiveness.\nTarleton and colleagues say the next step is to see if their promising results can be replicated in a larger, more diverse population.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release didn\u2019t mention either the funding sources or address conflicts of interest. These were noted in the study and could have been easily included in the release.", "answer": 0}, {"article": "GeneSight's test is covered by Medicare for patients under the care of psychiatrists and who have failed to achieve satisfactory results with at least one antidepressant. The company has coverage with some commercial payers and is working to widen that coverage, said Myriad Genetics spokesman Ron Rogers. The Genomind Genecept Assay is partly covered by Medicare and Medicaid. If the out-of-pocket cost for people with commercial plans is more than $300, Genomind will contact the client before processing the test. The company also has a financial assistance program for uninsured patients.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "As noted above, it should have been made clear that the May 2018 \u201clarge-scale test\u201d is unpublished and funded by the test sponsor.\nThe same goes for the Genecept paper that is cited by the company\u2019s VP: it\u2019s an industry-sponsored review paper \u2014 not original research \u2014 and cannot\u00a0 make claims about improved clinical outcomes or reduced overall medical costs from genetic testing.\nWe were pleased to see two independent sources cited, one of which provided a critical perspective.", "answer": 0}, {"article": "In a three-year study of more than 1,300 people with knee osteoarthritis, digital X-rays revealed substantially less loss of cartilage in the joint space in those who took strontium ranelate every day compared with people who took a placebo daily.\nStudy head Jean-Yves Reginster, MD, PhD, presented the findings today at the American College of Rheumatology (ACR) Annual Meeting in Washington, D.C.\nHe is president and chair of the department of public health sciences at the University of Li\u00e8ge in Belgium.\nThe wearing away of cartilage leads to pain and other symptoms.\nNearly one in 100 people have evidence of knee osteoarthritis on an X-ray.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides comments from a spokesman for the American College of Rheumatology. It also notes that several researchers reported financial ties to drug companies, including Servier Laboratories, which\u00a0makes\u00a0strontium ranelate.\n\u00a0", "answer": 1}, {"article": "Brain imaging has become a popular subject of research in recent years as the technology to be able to scan, store and analyze the terabytes of information in the pictures has become more affordable.\n\"Why some toddlers with ASD get better and develop good language and others do not has been a mystery that is of the utmost importance to solve,\" Eric Courchesne, one of the study\u2019s authors and co-director of the University of California-San Diego's Autism Center, said in a statement.\nThere\u2019s no such thing as a blood test, cheek swab or other accepted biological marker so specialists must depend on parent and teacher reports, observations and play assessments.\nThe spectrum is wide and some are destined to be on the mild end and be very talkative, sometimes almost indistinguishable from those without the disorder in some settings, while others will suffer from a more severe form and have trouble being able to speak basic words.\nNow scientists believe that they have a way to distinguish between those paths, at least in terms of language ability, in the toddler years using brain imaging.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The source quotes only one source \u2014 a study co-author. We see this as a drawback since there are numerous autism experts available, many of them holding differing views on autism diagnosis and treatment. As a service to reporters, HealthNewsReview.org maintains a list of independent experts who are willing to comment on studies and related news on health interventions.", "answer": 0}, {"article": "An experimental drug designed by Roche Holding AG's Genentech unit against a new cancer target yielded encouraging results against two rare tumors, researchers said, potentially opening up a new front in the battle against the disease.\n\nIn a small study, the drug, known as GDC-0449, shrank tumors in 18 of 33 patients, or 55%, with an advanced form of a skin cancer called basal cell carcinoma. In addition, the drug had a dramatic, though temporary, effect on a 26-year-old patient who had undergone multiple surgeries, chemotherapy...", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story provided comments from co-authors of the two studies, as well as the author of the accompanying editorial. \u00a0 ", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2009/11/02/financial/f035110S68.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story only includes a quote from the principle investigator, Paul Kwo (not Quo, as written erroneously in the story).\u00a0 ", "answer": 0}, {"article": "\u201cI was cute as button \u2014 and there was my double chin,\u201d she said.\nBy middle age, Ms. Gallagher, 51, the owner of a pet-sitting business in Torrance, Calif., was avoiding mirrors and considering liposuction, but she worried about the effects of anesthesia and the recovery time.\nAs an adult, she faithfully performed facial exercises purported to tighten the area under the chin.\nThen she discovered another option: a series of fat-reducing injections intended to slim down a double chin.\nShe stood ramrod-straight, head held high, to make the bulge less apparent.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This story provides comments from two experts in the field not associated with the clinical trials or the drug company. Compared with the Post\u2019s news-release based coverage, this yields additional depth and perspective regarding patient selection and potential harms. The story also notes that one quoted source is a paid consultant to the company.", "answer": 1}, {"article": "Viagra, known generically as sildenafil, is sold by Pfizer Inc for erectile dysfunction and under the brand name Revatio to treat a heart condition called pulmonary hypertension.\n\u201cAlthough PDE5 inhibitors will certainly not cure DMD, the current studies suggest that they could be used in combination with current or future therapies,\u201d the researchers wrote.\nIt slowed the damage and in some cases reversed it, they found.\nIt is not clear just how the drug is helping the mice, they reported in the Proceedings of the National Academy of Sciences, but they said it may be worth trying it as a treatment for muscular dystrophy.\nWASHINGTON (Reuters) - Viagra, developed to help ailing hearts long before it got a more high-profile job fighting erectile dysfunction, might help treat heart symptoms of muscular dystrophy, researchers reported on Monday.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\n\n\nThe story gets credit for reporting that the study was funded by the NIH and non-profit groups. But it does not appear that anyone was interviewed for this story, neither researchers nor independent experts. The quotes are excerpts from the journal article.", "answer": 0}, {"article": "Subsequent actions by PGC1-alpha then stimulate cells to produce more mitochondria.\nSo it has long been puzzling that exercise, in which energy is expended, is good for health, not bad.\nA drug that prolongs life, averts degenerative disease and, on top of all that, makes you into a champion athlete \u2014 at least if you are a mouse \u2014 sounds almost too good to be true.\nThat is the process that he says is reversed by resveratrol and, he hopes, by the more powerful sirtuin-activator drugs that his company is developing, though many years of clinical trials will still be needed to demonstrate whether they work and are safe to use.\nIn the latter case, Dr. Sinclair\u2019s and Dr. Auwerx\u2019s mouse experiments would offer less support to the sirtuin theory.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "While the story quoted several scientists not directly associated with the particular studies or companies mentioned, there was no balance to the perspectives represented.\u00a0 The story would have been greatly imporved if it had included some serious comment about the ramifcations of the scientific observations reported.", "answer": 0}, {"article": "By measuring the sternal notch-nipple distance and the nipple-inframammary fold distance ( proxies for upper and lower sensory ligament strength, respectively), the study found a differential rate of stretch - for every 1 cm in upper sensory ligament stretch, the lower sensory ligament length increases by 0.45 cm.\nThis study provides an anatomical foundation for why our technique may yield better, longer-lasting results.\"\nIn all patients, only one reduction technique was performed per patient.\n\"These results help us provide the best breast reduction outcomes to our patients.\"\n\"This study is one of the largest breast anthropometry (measurement) studies ever performed,\" says Lau.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t mention a funding source but that\u2019s understandable since the published study clearly states there is no conflict of interest and no funding source.", "answer": 1}, {"article": "Hospice care is intensive palliative care including home nursing, but insurers and Medicare usually cover it only if the patient abandons medical treatment and two doctors certify that death is less than six months away.\n\u201cBut I couldn\u2019t have completed the program without the psychosocial support.\u201d\n\nPalliative care experts now want to study patients with other cancers, heart disease, stroke, dementia and emphysema.\n\u201cThe billing is complicated, and for many physicians that\u2019s enough of a deterrent to not bother.\u201d\n\nDr. Cooney herself had such care along with surgery and chemotherapy for ovarian cancer in 2008.\nThis trial was paid for by the American Society of Clinical Oncology and private philanthropy.\nIt includes the options any oncologist addresses: surgery, chemotherapy and radiation and their side effects.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "A strong effort here. The story quotes one of the study authors,\u00a0an independent\u00a0editorialist, a physician-writer knowledgeable\u00a0about end-of-life\u00a0care,\u00a0as well as leaders of professional groups that support hospice and palliative care.\u00a0", "answer": 1}, {"article": "More than six million children in the United States have asthma, according to the Centers for Disease Control and Prevention, as do more than 330 million children and adults worldwide, according to the Global Asthma Network.\nThe author of that editorial, Dr. Christopher E. Ramsden, from the National Institutes of Health, said the findings would help doctors develop a \u201cprecision medicine\u201d approach in which fish-oil treatment could be tailored to women who are most likely to benefit.\nDr. Bisgaard said it was not possible to tell from the study whether pregnant women could benefit from simply eating more fish.\nAn editorial in the same journal by an expert who was not part of the study praised the research, saying it was well designed and carefully performed.\nThe research was paid for by the Danish government and private foundations.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story clearly explains who funded the study, and includes an independent source. But it doesn\u2019t note the extensive conflicts of interest reported by the lead author who\u2019s quoted in the piece:\nDr. Bisgaard reports receiving consulting fees from Chiesi Pharmaceuticals and Boehringer Ingelheim, and Drs. Bisgaard and B\u00f8nnelykke report being named on a pending patent related to the prevention of childhood asthma through FADS genotyping and the assessment of blood levels of eicosapentaenoic acid and docosahexaenoic acid in pregnant mothers.\nThe patent filing related to genetic testing is particularly relevant, given that the researcher advocates genetic testing and testing of fish oil levels in pregnant women to determine who might benefit most from supplementation.", "answer": 0}, {"article": "A sunscreen pill?\nWe've long assumed sunscreens will do the trick, but then came reports that the vitamin-A compound (retinyl palmitate) integral to many of them could actually be making us more melanoma-prone.\nA cautionary note:The damning evidence against vitamin A, which has long been used as a skin-cancer treatment, came from experiments done on mice, which have a far higher susceptibility to skin cancers than humans.\nAnd though dermatologists who have experience with Fernblock think it offers a measure of protection, even the manufacturer warns it won't suffice alone.\nAs an alternative, there's a relatively new product called Fernblock, which claims to protect the skin internally by systemically inhibiting the absorption of ultraviolet rays.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The sources independent from Fernblock\u2019s manufacturer and Reese Witherspoon are anonymous. There are\u00a0vague references to the opinions of \u201cmost\u201d dermatologists and to those dermatologists \u201cwho have experience with Fernblock.\u201d These generalizations are unverifiable, and thus of uncertain accuracy. Making a sweeping statement does not substitute for evidence or flesh-and-blood sources.\u00a0A comment about this product from a dermatologist or even someone versed in herbal medicine would have given helpful context. There was also a link to an Environmental Working Group page about sunscreen, but we don\u2019t see information about sun pills, the point of this story.", "answer": 0}, {"article": "It may have a big impact on public health without requiring complicated counting of calories or nutrients.\u201d\n\nWomen who fasted for longer periods of time overnight had significantly better control over blood glucose concentrations.\nCo-authors include Loki Natarajan, Dorothy Sears and Sheri Hartman of UC San Diego; and Linda Gallo and Elva Arredondo of San Diego State University.\nThe findings were presented at the American Association of Cancer Research\u2019s annual meeting in Philadelphia.\nFunding for this research came, in part, from the National Cancer Institute-sponsored Ruth L. Kirschstein National Research Service Award (1F31CA183125-01A1), the NCI Centers for Transdisciplinary Research on Energetics and Cancer (1U54CA155435-01) and philanthropic support from Ms. Carol Vassiliadis and family.\n\u201cThis is a simple dietary change that we believe most women can understand and adopt.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources are clearly stated at the end of the press release. There are no apparent conflicts of interest.", "answer": 1}, {"article": "\"It's clear that these medications are beneficial,\" said Wadden, who has been a paid consultant to pharmaceutical companies as well as Weight Watchers. \"Unfortunately, there's a sense that they must not work if you have to take them indefinitely. But I think obesity medications should be used on a long-term basis for chronic weight management, just as I take a [cholesterol-lowering] statin and a blood-pressure medication for the long term.\"", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story could have brought in some independent voices, which is why we gave it an unsatisfactory here. It did note that one of the authors had been a paid consultant for the pharmaceutical industry and for Weight Watchers, which was good to see disclosed.", "answer": 0}, {"article": "As we cut calories and lose weight, our resting metabolic rate eventually slows and our bodies become less efficient at shedding mass in a process known as adaptive thermogenesis.\nFor the small study just published in the International Journal of Obesity, the team enlisted 51 obese men from the ages of 25 to 54 years old.\nAnd while it\u2019s common to regain a few pounds after returning to previous eating habits, the two-week dieters kept the pounds off, maintaining a nearly 18-pound loss six months after the study.\nThis story was updated to include analysis from weight loss researcher Krista Varady, PhD, a nutrition professor at the University of Illinois, Chicago.\nKrista Varady, an outside researcher who studies intermittent fasting (not the same as intermittent dieting) and weight loss at the University of Illinois, believes the results were significant.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The article included an \u201coutside researcher\u201d who has some bona fides in the study of intermittent fasting, albeit not dieting, and quotes her essentially saying that the findings were significant and made sense to someone who studies dieting challenges.", "answer": 1}, {"article": "Previous studies have shown that the NRF2 gene controls cell functions in lung cancer tumors that helps them thwart the effect of chemotherapies that might otherwise reduce or eliminate them entirely.\nDr. Kmiec said the lung cancer work reflects an approach adopted by the Gene Editing Institute to move cautiously in developing medical applications of gene editing.\nThe study was led by Pawel Bialk, research scientist at the Gene Editing Institute, the nation's only CRISPR-focused research initiative situated in a community health care system.\nBut he said there continues to be significant safety concerns around this type of CRISPR application.\nHe said for now, his team is focused on \"using CRISPR in its native form, which is to just cut out a section of DNA,\" and to start with applications that do not directly impact the patient's DNA.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funders (NIH and State of Delaware) are noted on a sidebar on the EurekAlert! site which hosts the release. We encourage news release authors to include funding sources in the body of the release as well.\nThe authors did not report any conflicts of interest.", "answer": 1}, {"article": "\u201cThat\u2019s the ideal situation,\u201d he says.\nTheir next step is to \u201chumanize\u201d the antibody, so it can be tested without triggering an immune response.\n\u201cOsteoporosis and obesity are fairly closely linked in several ways,\u201d he tells Newsweek.\nAnd the population that could be most benefited by this could be post-menopausal women.\u201d\n\nCommenting on the research, Tim Speckor, Professor of Genetic Epidemiology at King\u2019s College London, U.K., says: \u201cIt\u2019s a nice mouse study that seems to work\u2014whether it works in humans is another matter.\u201d\nMice a fairly close genetic match to Humans, and Zaidi is hopeful there will be similar effects in humans.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does cite one independent source, but only in the very last paragraph. The story does not tell readers who funded the research, nor does it note that a provisional patent has been filed for the antibody. This is particularly relevant given that the scientist listed as inventor on that patent, and who would therefore receive royalties and/or licensing fees if the antibody is commercialized, is the same researcher who is quoted throughout the article about the potential impact of the antibody.", "answer": 0}, {"article": "Also, scar tissue often builds up around intravenous wires, a process that can make removing and replacing them difficult or dangerous.\nIn the study published Wednesday, Dr. Bardy and others reported that the new device had undergone several successful initial trials, including one in which it was used for a year in about 60 patients.\nBut Dr. Bardy estimated that the device could work in about 25 percent of patients who now get a defibrillator.\nThe device is being developed by Cameron Health, a small company in San Clemente, Calif., that was co-founded by Dr. Bardy.\nDr. Bardy said the cost of the new device is about the same as a standard defibrillator.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "\nThe story includes an independent source. It points out that the trials of the new device were paid for by the manufacturer and that the lead researcher founded the company.", "answer": 1}, {"article": "According to the U.S. Department of Agriculture\u2019s 2010 Dietary Guidelines, most Americans don\u2019t get enough fiber.\n\u201cIncreasing dietary fiber intake in the general public is of great public health significance,\u201d the Chinese team concludes.\nThat was after accounting for differences in risk factors like alcohol drinking, weight, hormone replacement therapy and family members with the disease.\nThe results \u201ccan identify associations but cannot tell us what will happen if people change their behavior,\u201d said John Pierce, a cancer research at the University of California, San Diego, who was not involved in the work.\nIf it turns out to cut cancer risk as well, that would be an extra bonus, Clarke said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Two expert independent perspectives were included.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061105/13healy.htm was not found on this server.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story only quotes the lead author of the recent study, Claudia Henschke. The story should have quoted other clinicians or researchers who could have provided some much needed balance.", "answer": 0}, {"article": "Professor Elwood said: \"Our review, based on the available evidence, suggests that low-dose aspirin taken by patients with bowel, breast or prostate cancer, in addition to other treatments, is associated with a reduction in deaths of about 15-20%, together with a reduction in the spread of the cancer.\nThat's why we specifically looked at the available evidence of bleeding and we wrote to all authors asking for further data.\n\"Whilst we know a low-dose of aspirin has been shown to reduce the incidence of cancer, its role in the treatment of cancer remains uncertain.\n\"The results from six studies of other cancers also suggest a reduction, but the numbers of patients were too few to enable confident interpretation.\n\"One of the concerns about taking aspirin remains the potential for intestinal bleeding.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "Funding sources and potential conflicts of interest weren\u2019t noted in the release. The study, published in PLoS ONE,\u00a0 however, declares no conflicts of interest and \u2014 curiously \u2014 no support or funding, either.\nBut since this type of study is based on analyzing others\u2019 results, we\u2019ll go out on a limb to assume that the researchers\u2019 institutions backed it in the form of their usual salaries. In any case, we want to see these items clarified in news releases.", "answer": 0}, {"article": "The U.S. National Institutes of Health has more on insomnia.\nThat means, theoretically, fewer side effects and perhaps less of a tendency to be habit forming, Thorpy explained.\nMore than 30 million Americans struggle to get a good night's sleep, and about one-third of these use drugs to help the process, the study authors pointed out.\nBut many questions remain: Do the drugs truly have fewer side effects?\nExperts note that findings from animal studies do not always hold up in human trials.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story reports that the researchers work for Merck, the maker of a drug similar to the one they tested. It also includes comments from two independent sources. This story does a better job of providing independent perspectives than the Reuters story we also reviewed. But neither unaffiliated expert points out the study design and the inherent liabilities in interpretation to humans.", "answer": 1}, {"article": "As myelin damage continues over the course of the disease, neurons progressively lose their ability to reliably transmit electrical signals, resulting in progressive loss of vision, weakness, walking difficulties, and problems with coordination and balance.\nThe new results are particularly notable, Chan said, because patients in the trial had suffered from MS symptoms caused by injury to myelin for years.\nThat myelin increases the speed of neural transmission is one of the most well-established concepts in neurobiology, and combined with the clear evidence from Chan's preclinical research showing that clemastine fumarate promotes myelin formation, myelin regeneration is the only plausible explanation for the VEP results, the authors said.\nThis \"flip-flop\" technique gave the researchers the ability to compare patients to themselves -- a form of control that increased the statistical power of the study by nearly an order of magnitude, Green said.\nIt's not a cure, but it's a first step towards restoring brain function to the millions who are affected by this chronic, debilitating disease,\" said the trial's principal investigator, Ari Green, MD, also Debbie and Andy Rachleff Distinguished Professor of Neurology, chief of the Division of Neuroinflammation and Glial Biology, and medical director of the UCSF Multiple Sclerosis and Neuroinflammation Center.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release mentions that work was funded by the Rachleff Family.\nHowever, five out of 18 authors, including the first author, had multiple competing interests, mostly in the form of personal and consulting fees from the world\u2019s largest pharmaceutical companies according to the original journal report. Those conflicts should have been mentioned in the news release.", "answer": 0}, {"article": "Some doctors say the increased rate of Caesareans is partially attributable to maternal demand: busy mothers may want to schedule their deliveries.\nAnd some women are scheduling them early.\nBut opinion differs on how to respond.\nBut defining medical necessity is complicated.\nThis, according to Lake, the executive producer of the film, and Abby Epstein, the film's director, is the right reaction: one of their messages is that C-sections should only be performed when needed to guarantee the well-being of the mother and infant, and should not be a first choice for healthy mothers.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes multiple sources, however only two of them are clinical experts, the others are authors of books or filmmakers.", "answer": 1}, {"article": "Open and laparoscopic surgeries were still more common than robotic surgeries for kidney repairs and removals.\n\u201cYears ago, this was thought to be the be-all-end-all operation, particularly with prostate surgery.\n\"And the reality of it is that... there are some benefits -- but not as much as we had hoped.\"\nEmphasis should be lmited on procedure, he said, as opposed to surgical skill.\nThe open-surgery group also stayed in the hospital about one day longer than the robotic group.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included some input from the editorial writer \u2013 although, as stated above in the \u201cEvidence\u201d criterion \u2013 perhaps not to its greatest effectiveness.\n\u00a0", "answer": 1}, {"article": "Between 12% and 20% of women in the 35 countries in the Organisation for Economic Co-operation and Development suffer from perinatal depression, and 20-35% in poorer countries.\nThe NHS website explains that it is \u201cbased on the concept that your thoughts, feelings, physical sensations and actions are interconnected, and that negative thoughts and feelings can trap you in a vicious cycle\u201d.\n\u201cThis is an important study for the impact on mothers with depression but there are global implications for the treatment of all human beings suffering from depression.\nThere were also big improvements in their parenting style.\n\u201cThese findings on the longer-term benefits at seven years post-treatment are really exciting,\u201d Bhalotra said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not quote anyone independent of this study; this would have been very useful to include considering this is unpublished data (as far as we can tell).", "answer": 0}, {"article": "Many women have been reluctant to use hormones for menopause symptoms since 2002, when the federally funded Women\u2019s Health Initiative (WHI) study linked the treatments containing man-made versions of the female hormones estrogen and progestin to an increased risk of breast cancer, heart attacks and strokes.\nWith additional years of follow-up, it also appears that the increased heart attack risk associated with HRT in the initial results from the WHI trials is limited to older women, McNeil added.\nTaking a combination of estrogen and progestin is associated with an increased risk of breast cancer, but advances in screening and treatment since the WHI started now mean these tumors are unlikely to be fatal, McNeil said by email.\nStill, the current study should ease concerns raised by earlier results from the WHI trials that an increased risk of breast cancer or heart attacks might translate into higher long-term mortality rates, said Dr. Melissa McNeil, author of an accompanying editorial and a women\u2019s health researcher at the University of Pittsburgh.\n\u201cWomen seeking treatment for distressing hot flashes, night sweats or other menopausal symptoms may find the mortality results reassuring,\u201d said lead study author Dr. JoAnn Manson of Brigham and Women\u2019s Hospital and Harvard Medical School in Boston.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included an independent source and there does not appear any conflicts of interest that should have been disclosed.", "answer": 1}, {"article": "Referring to Lozano's second clinical study, Dr. Nader Pouratian, a neurosurgeon and DBS researcher at UCLA, comments, \"The recent deep brain stimulation trial for Alzheimer's disease clearly demonstrates the safety of this approach for trying to treat the progression of disease.\nGiven that so few people have had electrical stimulation applied to memory circuits, perhaps the most significant finding was that both the surgery itself and DBS of the fornix appear safe.\nUsing a 3-dimensional brain mapping technique called standardized low-resolution brain electromagnetic tomography, or sLORETA, Lozano's group uncovered an explanation for the unexpected findings.\nYet the fact that the therapy can in some people rescue recollections \u2013 albeit random ones \u2013 and possibly induce new neuron growth in memory regions of the brain seems reason enough to pursue it further.\nThe woman is a patient of Dr. Andres Lozano, a neurosurgeon who is among a growing number of researchers studying the potential of deep brain stimulation to treat Alzheimer's and other forms of dementia.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story cites multiple sources but fails to mention research funding or potential or conflicts of interest. Notably, it omits the fact that one researcher at the center of this story, University of Toronto neuroscientist Andres Lozano, M.D., has a financial interest in the deep brain stimulation as co-founder and director of Functional Neuromodulation Inc, which makes the deep brain stimulation device.", "answer": 0}, {"article": "In a healthy brain, microglia act as chemical rubbish collectors, surveying the local environment, clearing up unwanted compounds, but in Alzheimer\u2019s these cells can lose this function and switch into an inflammatory state in which they secrete toxic compounds instead.\nThe study, published on Wednesday in the journal Nature, hinges on the observation that Alzheimer\u2019s patients show a loss of synchronised brain activity, known as gamma oscillations, which is linked to attention and memory.\nThe authors caution that a \u201cbig if\u201d remains over whether the findings would be replicated in humans \u2013 and whether cognitive deficits as well as visible symptoms of the disease would be improved.\n\u201cIf humans behave similarly to mice in response to this treatment, I would say the potential is just enormous, because it\u2019s so non-invasive, and it\u2019s so accessible,\u201d said Li-Huei Tsai, director of the Picower Institute for Learning and Memory at MIT, and the paper\u2019s senior author.\nAt 40Hz the flicker of the light is barely discernible and would be \u201cnot offensive at all\u201d for a person to have in the background.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The senior author of the study is cited (and\u00a0her quote came from an unattributed news release, see last criterion, below), but so are other researchers. Independent sources appear to have been consulted.\u00a0The story also notes that the author has formed a company to pursue this, which is an important conflict of interest disclosure.", "answer": 1}, {"article": "Although the use of NSAIDs for arthritic conditions such as knee OA has potential risks, including heart attack and stroke, existing evidence indicates that naproxen has less potential for adverse cardiovascular events.\n\"While the information in this analysis is helpful to physicians, patients also can benefit from these findings and use it with their doctors to weigh all possible treatment options.\"\nMore information about the AAOS and JAAOS\n\nFollow the AAOS on Facebook, Twitter and Instagram \n\nFollow the conversation about JAAOS on Twitter\n\nFrom the Department of Orthopaedics, Dartmouth-Hitchcock Medical Center, Lebanon, NH (Dr. Jevsevar), American Academy of Orthopaedic Surgeons, Rosemont, IL (Mr. Shores, Mr. Mullen, Ms. Schulte, and Dr. Cummins), and Franciscan Orthopedic Associates, Tacoma, WA (Dr. Brown).\n\u2022 HA injections did not achieve a rank in the top five treatments for pain, function, or combined pain and function.\n\"Because knee OA has both a high disease burden and high treatment costs, additional prospective studies using similar outcomes, timelines, and measures of clinically important changes are needed,\" explained Dr. Jevsevar.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release identifies only where the authors work. It does not include the disclosures listed in the journal article. These disclosures should have been included in the news release.", "answer": 0}, {"article": "A little bit of current may calm the tremors of Parkinson\ufffds disease, ease depression and epilepsy, and awaken those with terrible injuries.\nA glimpse of Mom must first register on your occipital lobes as a pattern of light and shadow.\nFrom there it is relayed to your memory center, where it is identified by comparison with every other face you've ever seen.\nIt's harder than you think to say hello to your mother--at least in terms of the work your brain has to do.\nA lateral X-Ray of the head of a 38-year-old man shows two Deep Brain Stimulation (DBS) leads with four electrodes attached to each implanted in the subcortical area of the brain called the thalamus.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story quotes three of the authors of a published study; in addition it contains interview material from a person being treated that had Parkinson\u2019s disease as well as another clinician who did not appear to contribute to this publication.\nHowever \u2013 there was no one with an expertise in the miminally concious state not connected with this particular\u00a0technology in some way who appears to have been interviewed for this story.\u00a0 ", "answer": 0}, {"article": "See original publication for details.\nMoreover, the scientists \u2013 together with colleagues in Barcelona and from the CIMBA* consortium mapping more than 23,000 women \u2013 showed that genetic variants in the RANK gene are associated with a higher risk of developing breast cancer in women who carry BRCA1 and also BRCA2 mutations.\nIn the current study, Verena Sigl, graduate student from Penninger's research group, showed that blocking the RANKL/RANK system in BRCA1 mutant mice led to largely normal mammary glands whereas invasive carcinomas could be found in the control group.\nIn the human cell culture, too, RANKL inhibition led to a significant reduction of growth and spreading of breast tissue cells.\nScientists at the University of Maryland School of Medicine in Baltimore have already tried the preventive use of a RANKL blocking drug in mice.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release states that the research received funding from the U.S. Department of Defense but it doesn\u2019t provide other important information that adds transparency. According to the published study, the Institute of Molecular Bioltechnology has applied for a patent on using RANKL inhibition to block breast cancer and that Amgen, Inc. (the maker of denosumab) provided RANK-Fc and financial support for the study.", "answer": 0}, {"article": "\u201cThe goal for the user is to keep five green dots.\nDry air can also exacerbate some illnesses and can be a problem as well.\u201d\n\nDifferent sources of air pollution in your home could include paints that release lead or volatile organic compounds (VOCs), carpets that harbor dirt, dust mites, and fungus and even nitrogen dioxide from gas stoves, but these aren\u2019t the worst culprits, Lahita said.\nIt analyzes the data in real-time and gives an Awair score on a 0 to 100 color-coded scale, 0 being the worst air quality.\n\u201cLow dry humidity in the winter can make asthma worse and children who have dried mucosa can acquire some nasal infections easier,\u201d Dr. Robert G. Lahita, chairman of medicine at Newark Beth Israel Medical Center in New Jersey, told FoxNews.com.\nWhile breathing fresh, clean air can boost productivity, sleep and overall health, not everyone can live in the great outdoors and it\u2019s difficult to know just how clean the indoor air in your home or office is.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "This is satisfactory, but barely. The story does quote a physician with no obvious ties to Awair about how air quality may affect health. What\u2019s not clear is why the reporter chose to spoke to the physician, who specializes in rheumatism, arthritis and related ailments. More importantly, the story is missing any independent sources who can weigh in on Awair, or how effective it may be at reducing any kind of health risk.", "answer": 1}, {"article": "As most C. trachomatis infections are asymptomatic, chlamydia can often go untreated and lead to upper genital tract infections, pelvic inflammatory disease, and infertility.\nThe study was funded by the Canadian Institutes for Health Research.\nThe results look very promising, said senior author James Mahony, a professor of Pathology and Molecular Medicine for McMaster's Michael G. DeGroote School of Medicine and a researcher at St. Joseph Healthcare Hamilton's Research Institute where the work was performed.\nThis is why the promise of a vaccine would be extremely beneficial, says David Bulir, co-author of the study.\n\"Vaccination would be the best way to way to prevent a chlamydia infection, and this study has identified important new antigens which could be used as part of a vaccine to prevent or eliminate the damaging reproductive consequences of untreated infections.\"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release notes that the Canadian Institutes for Health Research funded the study.", "answer": 1}, {"article": "Now, she said, \u201cI\u2019m out walking my Lab about five miles a day, every day.\nLast year, the average salary for joint-replacement specialists topped $575,000, reported the Dallas consulting firm Merritt Hawkins & Associates, compared with just over $230,000 for family doctors.\n\u201cWe thought we\u2019d be young forever,\u201d said Francis, who co-anchors a radio news program in Washington, D.C. \u201cThe big wake-up call is when our bodies wear down.\u201d\n\nBaby boomers, determined to keep moving no matter what wear and tear and arthritis have wrought, are fueling a surge in joint replacements.\nIt sells between 17,000 and 20,000 personalized knee implants a year \u2014 still a small share of the market \u2014 and last year won US regulatory approval for its first hip implants.\nWest Newbury\u2019s town clerk, Mike McCarron,, 62, played high school and college football and once climbed Mount Washington in the winter.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story admirably reported the generous pay of doctors who do joint replacements: \u201cLast year, the average salary for joint-replacement specialists topped $575,000, reported the Dallas consulting firm Merritt Hawkins & Associates, compared with just over $230,000 for family doctors.\u201d\nBut the story doesn\u2019t tell readers that the only doctor it quotes \u2014 orthopedic surgeon David Mattingly, M.D. \u2014 has received $160,000 from joint maker DePuy Synthes, a division of Johnson & Johnson, in recent years, according to the database Open Payments.\nIt would have been good to quote a doctor who doesn\u2019t make a living doing these surgeries (e.g. an internist or sports medicine doctor who treats hip and knee osteoarthritis).", "answer": 0}, {"article": "Such regular use of low-dose aspirin reduced the risk by 20 percent of estrogen or progesterone receptor positive, HER2 negative breast cancer, which is the most common breast cancer subtype.\nThe content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.\nThe team of researchers chose to focus on low-dose \"baby\" aspirin, because not only is it inexpensive and readily available as potential means of prevention, but because there are already a lot of people already taking it for prevention of other diseases such as heart disease and even colon cancer.\nNow that we have some data separating low-dose from higher-dose aspirin, more detailed research can be undertaken to understand the full value of low-dose aspirin for breast cancer prevention,\" said Clarke.\"\n\"The study found an interesting protective association between low-dose aspirin and breast cancer,\" said lead author Christina A. Clarke, Ph.D., M.P.H., from the Cancer Prevention Institute of California.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly identifies the sources of funding. It does not address conflicts of interest, but there do not appear to be any relevant conflicts of interest. Still, the release would have been stronger if it had stated that explicitly.", "answer": 1}, {"article": "But in the study group overall, more-inflammatory diets were not linked to fracture and - in fact - the researchers found a modestly lower risk of lower-arm and total fracture in women with the highest dietary inflammation scores.\nVedat Yildiz of Ohio State's Center for Biostatistics also worked on the study, which was supported by the National Heart, Lung and Blood Institute and the U.S. Department of Health and Human Services.\nThe study, led by Tonya Orchard, an assistant professor of human nutrition at The Ohio State University, appears in the Journal of Bone and Mineral Research.\nRebecca Jackson, the study's senior author and director of Ohio State's Center for Clinical and Translational Science, said the new findings support a growing body of evidence that factors that increase inflammation can increase osteoporosis risk.\nThe researchers used bone-mineral-density data from a subset of 10,290 women.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release explains that the study was funded by\u00a0the National Heart, Lung and Blood Institute and the U.S. Department of Health and Human Services.", "answer": 1}, {"article": "A fourth drug, GlaxoSmithKline\u2019s and Biota Inc\u2019s Relenza, works by the same mechanism as Tamiflu.\nBecause Fludase affects the human cells that viruses infect, not the virus itself, it is less likely to cause the virus to develop resistance, the company believes.\nAdding parainfluenza to its approved indications would provide a unique and potentially large market for San Diego-based NexBio.\nA spokesman for NexBio, David Wurtman, said the company would seek Food and Drug Administration approval to test Fludase in people with parainfluenza.\n\u201cTherapies for parainfluenza are urgently needed,\u201d Moscona, an expert on parainfluenza viruses, said in a statement.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "       \n \nThe story fails in just about every aspect of this criterion.\u00a0No experts  in the field other than those involved in the research study are  quoted.\u00a0Interestingly, 6 of the 9 authors of the study are employees of  NexBio, the company that produces the drug.\u00a0One of the authors is listed  as the inventor of the drug in an approved patent for its use in the  treatment of influenza and parainfluenza.\u00a0While these facts do not necessarily impugn the study result, failure to note them in the story is a major  omission.\n ", "answer": 0}, {"article": ".\nIn the current analysis of treatment between 6 and 24 hours after symptoms were observed, or after the person was last seen to be well, researchers found:\n\u2022 each 1-hour delay reduces the chance of recovery with minimal or no disability by 11 percent; and\n\u2022 treatment remains beneficial through 24 hours, with patients who had their clots removed being 35.5 percent more likely to have minimal or no disability 90 days later, but the overall effect of treatment declines with time.\nLOS ANGELES, Jan. 25, 2018 -- Clot removal may be beneficial up to 24 hours following stroke in carefully selected patients, but every hour delayed after symptoms begin may be associated with more disability, according to preliminary research presented at the American Stroke Association's International Stroke Conference 2018, a world premier meeting dedicated to the science and treatment of cerebrovascular disease for researchers and clinicians.\nThe association has strict policies to prevent these relationships from influencing the science content.\nThe international DAWN trial previously demonstrated that patients with a small area of irreversible brain damage and a large area of brain at jeopardy of being lost if the clot remains are more likely to recover with minimal disability if the clot is removed up to 24 hours after symptoms begin or were noticed.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release mentions that the DAWN trial was funded by\u00a0Stryker Neuroendovascular. What it did not mention is that Stryker is a company that produces medical devices, and their device for clot removal was the only one used in the trial. Presumably, the good results from this trial will lead to an uptick in their product sales. Indeed, the news release from Stryker contains a lot more information about the specific product compared to this news release.\nWhile many journalists reading the release will understand who Stryker is and why this represents a conflict of interest, consumers reading a reposted version of the release may not have that context. For their benefit, it would be better to spell things out directly.", "answer": 1}, {"article": "Nearly 25 percent of those ages 65 to 74 and 50 percent of those who are 75 and older have disabling hearing loss.\n\u201cOn average, patients performed more than twice as well on tests of speech understanding with EAS than they did with their hearing aids preoperatively, which speaks to the benefits of this technology,\u201d Pillsbury said.\nNinety-seven percent of patients participating in the MED-EL EAS clinical trial reported a benefit from EAS within the first year.\nUNC participated in the EAS System clinical trials and implanted the device in more patients than any other hearing center that participated.\nMED-EL expects that the SYNCHRONY EAS Hearing Implant System will be available in the coming months.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release needed information about funding sources for the clinical trials. In addition, the release does not explain the quoted source\u2019s relationship to the study (although it is implied that he is helping to lead it).", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/09/national/a005536S75.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Sources do not appear to have conflicts of interest, and none are noted. The CDC and VP of Pediatric AIDS Foundation seem to be balanced sources without ties to pharmaceutical companies. How the nevirapine studies are funded would be good to note.", "answer": 1}, {"article": "I couldn't get anything done,\" Ham said.\nBut he urged caution.\nThen, a friend mentioned marijuana, which Maine had legalized in 1999 for chronic pain and scores of other medical conditions.\n\"They have greater respect.\nBolstered by stories like Ham's, doctors are experimenting with marijuana as an addiction treatment in Massachusetts and California.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There\u00a0sourcing is a strong point for the story. Also,\u00a0there are no apparent conflicts of interest.", "answer": 1}, {"article": "The researchers wanted to evaluate whether in a group of women suffering from severe menstrual pain, aged between 18 and 34, self-acupressure would be more effective at achieving a sustained reduction in menstrual pain than usual care alone (e.g.\nAdditionally, the app was used to collect all study-related data.\nIt can also send regular reminders.\nThe app helped participants to apply simple self-acupressure techniques to three different acupressure points.\nThe app Luna has recently been updated and optimized for use with iOS.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release doesn\u2019t say how the research was funded. The last line of the release notes the trade name of the app used in the study but not the developer.", "answer": 0}, {"article": "It tends to relieve depression, which is common among people with epilepsy.\nThe device is appealing because it doesn't require surgery, doesn't have side effects and is very easy to use, Rees says.\nThe trigeminal nerve stimulator, in contrast, never penetrates the skin and is powered by an external device about the size of a large cell phone, DeGiorgio says.\nAnd DeGiorgio says he's found an interesting benefit to trigeminal nerve stimulation.\nThe device causes \"a slight tingling sensation\" on her skin, she says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story does not use any independent sources. It also does not make it clear whether Christopher DeGiorgio, a UCLA doctor who invented the device, will benefit from it financially. One can presume that he will, but the story should have made that clear.", "answer": 0}, {"article": "Among them: engaging in regular physical activity, maintaining a healthy weight, and not smoking cigarettes.\nHe found an association, not cause and effect.\nEven so, he says, \"our results provide additional support for the potential benefit of daily aspirin for [reducing] cancer mortality.\"\nThe benefit, however, may not be as great as believed, says researcher Eric Jacobs, PhD, of the American Cancer Society.\nMany other strategies will also reduce the risk of cancer, he says.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Again, we\u2019ll take a hard-line approach.\nYes, the story had an additional source, an editorial writer.\u00a0 And yes, it disclosed the industry ties of that editorial writer and the fact that he holds a patent for chemoprevention use of aspirin.\nIt is understandable that the story would turn to Dr. Baron\u2019s comments, since he wrote the accompanying editorial and since he has published extensively on this topic.\nBut, by definition, since he was the only other source used, there was no independent source used in the story.\nBy contrast, Reuters had no problem finding a truly independent source.\n\u00a0", "answer": 0}, {"article": "Drs.\nInternational Study Finds Effective, Less Toxic Way to Treat Brain Tumors\n\nNewswise \u2014 CHARLOTTE, N.C., July 26, 2016 /PRNewswire-USNewswire/ -- Physicians from Carolinas HealthCare System's Neurosciences Institute and Levine Cancer Institute are among the authors of a study that was accepted for publication by the Journal of the American Medical Association (JAMA).\nAnthony L. Asher, MD, FACS, medical director at Carolinas HealthCare System's Neurosciences Institute and the senior author on the report, and as well as Stuart H. Burri, MD, chairman, department of radiation oncology at Levine Cancer Institute, began their research on this subject over 10 years ago in Charlotte, North Carolina.\nAsher and Burri, along with their co-investigators, now recommend that patients with one to three brain metastases should no longer receive routine whole brain radiation therapy, and should be treated with focused therapy alone to better preserve cognitive function and quality of life.\n\"Having the research published in JAMA is validation of more than a decade of work,\" says Dr. Burri. \"\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The funding source is not identified in the release. The release also makes no mention of conflicts of interest, but the journal article disclosure section notes only that one of the authors (not mentioned in the release) receives some industry funding.", "answer": 0}, {"article": "Both Prozac and Celexa belong to a class of antidepressants known as selective serotonin reuptake inhibitors, or SSRIs.\nResponding to the research, Yale Child Study Center director Fred Volkmar told WebMD: \u201cThe question remains, \u2018Is fluoxetine better than risperidone for this symptom?\u2019 It would be interesting to see studies comparing these two drugs head to head.\u201d\n\nHollander has previously received funding from pharmaceutical companies, but the current study was paid for by a grant from the Food and Drug Administration\u2019s \u201corphan\u201d drug program.\nWhen the research was originally funded, Hollander says, autism was considered to be a rare condition.\n\u201cIt takes the edge off,\u201d Hollander explains, noting that the findings were statistically significant and clinically meaningful.\nThe research, which included 37 high-functioning autistic adults, mainly diagnosed with Asperger\u2019s syndrome, followed participants for 12 weeks.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story briefly quotes another story in which Yale Child Study Center director Fred Volkmar commented on the study, indicating that more research was needed. We would have liked to have seen more independent voices helping readers understand whether there was anything new here. The story also says, \u201cHollander has previously received funding from pharmaceutical companies, but the current study was paid for by a grant from the Food and Drug Administration\u2019s \u201corphan\u201d drug program.\u201d\n\u00a0\n\u00a0", "answer": 1}, {"article": "Benign prostate hyperplasia, also known as enlarged prostate, is a non-cancerous condition familiar to millions of aging males.\nAnd while this study showed some symptomatic improvement, it didn't have enough objective data to show that the new technique would surpass surgery, she said.\nCurrent surgical procedures typically require no more than one night in the hospital and complications such as incontinence and impotence are uncommon, he said.\n\"PAE is potentially fraught with complications,\" Lowe said, adding that the study follow-up of less than one year was short for a disease that lasts decades.\nSince the study is being presented at a medical meeting and has not yet been published in a peer-reviewed journal, the findings should be considered preliminary.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Clinicians with expertise in treating benign prostatic hyperplasia and without apparent ties to the study reported on were quoted in this story.", "answer": 1}, {"article": "Macular edema can arise during any stage of diabetic retinopathy and is the most common cause of diabetes-related vision loss.\nThe clinical trial was conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net), which is funded by the National Eye Institute, part of the National Institutes of Health.\n\u201cThis important study would not have happened without funding from the National Institutes of Health and the cooperation of two competing companies,\u201d said Adam R. Glassman, M.S., principal investigator of the DRCR.Net Coordinating Center at the Jaeb Center for Health Research.\nAdditional research funding for this study was provided by the National Institute of Diabetes and Digestive and Kidney Diseases, also a part of NIH.\nWells, M.D., the lead author of the study and a retinal specialist at the Palmetto Retina Center, Columbia, South Carolina.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release clearly spells out that the trial was funded by the National Eye Institute, part of the National Institutes of Health. It further states that two drug companies provided their drugs for the trial.", "answer": 1}, {"article": "Inflammation associated with dry eye may eventually lead to damage to the surface of the eye.\nResults from inferior corneal staining tests \u2014 used by physicians to detect abrasions on the cornea \u2014 showed improvement in three of the four studies.\nShe focused on the cause and potential therapies for dry eye that are being funded through the National Eye Institute and in private industry.\nThere are more than 30-plus new dry eye basic, translational and clinical studies being funded by the NEI/National Institutes of Health to further explore these lipids and proteins, with more than 50 papers being published monthly.\n\u201cFunding from NIH is helping the optometry world make significant strides in understanding the cause and treatment of dry eye,\u201d Nichols said.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release acknowledges that the person quoted was doing work for Shire plc, the company that makes the product. The release was correct to include this funder as a potential conflict of interest. It would also have been good to note that study was conducted by by the UAB Center for Translational Research.", "answer": 1}, {"article": "Guyuron, chair of plastic surgery at University Hospitals Case Medical Center in Cleveland, went on to identify four common \"trigger sites\" and publish studies showing that, in selected patients, surgical decompression of nerves in one or more of these sites provides lasting migraine relief. He has also taught 250 plastic surgeons around the world (none in the Philadelphia area) to perform the outpatient operation, which costs an average of $10,000 and is not covered by many insurers.", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story takes far too long to bring in independent experts, and their voices, while strongly in opposition to surgery, may be drowned out by all the space devoted go Guyuron and his patients, who claim to have been miraculously cured. One has to wonder why a quote like this would not have made the newspaper have doubts about publishing the story: \u201c\u2019I know most of the headache experts in the country and they don\u2019t support\u2019 migraine surgery, said neurologist Stephen Silberstein, director of Thomas Jefferson University\u2019s Headache Center, one of the nation\u2019s leading programs. \u2018I certainly wouldn\u2019t recommend it, or say insurance should cover it\u2019 at this point. Neither would the American Headache Society, whose board includes Jefferson neurologist William Young.\u201d", "answer": 1}, {"article": "\u201cThat would be the quickest path to insolvency,\u201d he said.\nMr. Garabedian said Sarepta did not have the money or the manufacturing capacity to make the drug available outside of clinical trials.\nThat could make it harder for the Sarepta to win approval for the drug based only on this small trial, something the company hopes to do.\nBut Ms. McNary said Sarepta had refused to provide the drug to Max\u2019s 13-year-old brother, Austin, who could not be in the trial because he already could not walk.\n\u201cIf you wait and require this company to do another two-year study, a lot of these boys are going to be in a wheelchair,\u201d Christopher Garabedian, the Sarepta chief executive, said in an interview.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story is based on a pre-abstract release of information from the company.\u00a0 The study\u2019s principal investigator, the company CEO and parents of children enrolled in the study are the only sources quoted in the story.\u00a0 We think that an independent expert should have been quoted.", "answer": 0}, {"article": "They were divided in groups of 10.\nThe research was conducted when mice had developed memory problems.\nBrough, however, cautioned that further research is required to identify its impact on humans and the long-term implications.\n\u201cThere is experimental evidence now to strongly suggest that inflammation in the brain makes Alzheimer\u2019s disease worse.\n\u201cHowever, much more work needs to be done until we can say with certainty that it will tackle the disease in humans as mouse models don't always faithfully replicate the human disease.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "There\u00a0are no\u00a0independent sources in the story.", "answer": 0}, {"article": "All rights reserved.\nUsing one current method, 37 of the 395 men would have been called very low risk and good candidates for monitoring.\nHe said a gene test may have made him more comfortable with that decision.\n\"It went both ways \u2014 that was the remarkable thing.\n\"You can shop for a toaster\" better than for prostate treatment, he said.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Mixed bag.\nMultiple sources were interviewed \u2013 which was admirable.\nThe story could have explained that two of the experts quoted either had paid consultant arrangements or received research funding from one of the companies mentioned in the story.", "answer": 1}, {"article": "\n\u2022 Detailed Results of Phase 2 Trial Presented at the American College of Gastroenterology 2016 Annual Scientific Meeting\n\u2022 93.3% of Patients Treated Using the Lead Formulation of Novel Prep Achieved a Colonoscopy Rating of Excellent or Good, Compared to 85.7% of Those Using Standard Prep Products in Colonoscopist-blinded Trial\n\u2022 More 'Patient-friendly,' Palatable Prep Could Help Increase Patient Acceptance of Colonoscopies for Colorectal Cancer Screening\n\nNewton, MA (October 17, 2016) - Detailed results from a Phase 2 study of a novel colonoscopy prep (ECP) under development by ColonaryConcepts, LLC show the investigational treatment to be at least as effective and safe as two currently available colonoscopy prep formulations, while offering a much higher level of patient satisfaction and preference than standard preps.\n\"We are very pleased with the efficacy and safety results of this study, which clearly support advancing this product to a Phase 3 trial,\" said Corey A. Siegel, M.D., M.S., a co-founder of ColonaryConcepts, and Director of the Inflammatory Bowel Disease Center at the Dartmouth-Hitchcock Medical Center and Associate Professor of Medicine at The Geisel School of Medicine at Dartmouth.\n\"The ECP approach allows patients to eat solid food bars and drink palatable low-volume beverages, a patient-friendly design that participants in the study clearly favored over conventional preps,\" comments Dr. Siegel.\nThe company currently has two product candidates in clinical development: ECP, which is expected to enter Phase 3 clinical trials in early 2017, and the \"C-bar\", a novel product candidate for chronic constipation, which is currently being studied in a Phase 1b clinical trial.\nThe study tested six formulations of ECP, using different doses of the active ingredients integrated within different meal kit menus, randomized against two U.S. Food and Drug Administration-approved active comparators.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The developer of this prep, ColonaryConcepts, LLC, is clearly identified in the news release, and a couple of other sources are also clearly linked to the company.\u00a0 However, one source, identified as the principal investigator for the study, is described in a conference abstract as a consultant for the company, but that was not made clear in the release.", "answer": 0}, {"article": ".\nThese additional results of the Systolic Blood Pressure Intervention Trial (SPRINT) appear in the current online issue of the Journal of the American Medical Association (JAMA).\nWHO: Lawrence Fine, M.D., chief of the Clinical Applications and Prevention Branch at NHLBI and a co-author of the study, is available to comment on the findings and implications of this research.\nThe new analysis singles out adults aged 75 and older and confirms that those with high blood pressure also benefit from the lower pressure target similar to the larger group studied in the earlier research: non-diabetic adults aged 50 and older.\nTo address this issue, the SPRINT study tapped more than 2,600 volunteers aged 75 and older, assigning half to a target blood pressure of less than 140 mm Hg and half to target of less than 120 mm Hg.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "While this release does identify the main funding sources for the trial, it fails to mention any potential conflicts of interest, even though the paper itself discloses that three of the authors had numerous financial links to pharmaceutical firms.", "answer": 0}, {"article": "Stay in touch on Linkedin, on Twitter @EpicSciences or on Facebook.com/EpicSciences.\nAdditionally, the authors validated the test within a prognostic risk group, to ensure that the biomarker effect was due to the biomarker rather than other clinical variables.\nThe PROPHECY study investigated the AR-V7 test in patients receiving ARSi therapy and demonstrated that patients who tested positive had worse survival by all measures and had no clinical benefit from ARSi therapy.\nIn March of this year, based upon earlier studies utilizing the test, Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies, issued a draft local coverage determination (LCD) for the Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 test.\nThis is the second blinded, multi-center clinical utility validation study utilizing the nuclear-localized AR-V7 test.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The release states that Epic Sciences \u201cdesigned\u201d the test and that different research institutions led research studies on the blood test. The release could have been much more transparent about who funded the research.\nThe study didn\u2019t mention all of the researchers\u2019 industry ties, but it did mention that some of the researchers are employed by Epic Sciences, the developer of the test.", "answer": 0}, {"article": "Side effects of male hormone therapy can include erectile dysfunction (impotence), loss of sex drive, hot flashes, growth of breast tissue, loss of muscle and bone mass, weight gain, nausea, liver problems, fatigue, memory problems and mood swings.\nThe report was published in the July 14 issue of the New England Journal of Medicine.\nHe noted that the radiation treatments in use today differ from those given in 1994 when the trial began.\nThese findings are good news for some men, since the effects of short term of hormone therapy are reversible, D'Amico said.\nSo, that brings into question how much, if any, hormone therapy is needed, he added.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story included quotes from the lead author of the study reported on along with quotes from the expert in the field who wrote an editorial about the study which accompanied its publication.", "answer": 1}, {"article": "METs, or metabolic equivalents, are a measure of physiological measure expressing the energy cost of physical activities.\nThese differences in risk were statistically significant.\nBased on the results, Dr Hupin said that a revision of the recommendations for physical activity in the elderly may thus be warranted and beneficial - low dose physical activity can significantly reduce mortality.\nDr Hupin emphasised that the widespread acceptance of this message would encourage more elderly people to include even \"low doses\" of physical activity in their usual daily activities, without experiencing high levels of fatigue or of pain.\nIn commenting on the results, Dr Hupin said several conclusions might be drawn but notably that the level of physical activity in the elderly was negatively associated with mortality rate in a \"dose-dependent\" way and that even a low level of exercise below current recommendations had some protective effect.\n", "question": "Does the news release identify funding sources & disclose conflicts of interest?", "explanation": "The news release does not mention any funding sources for the study or potential conflicts of interest.", "answer": 0}, {"article": "Unfortunately, condoms and vasectomy have remained the only commercially available contraception options for men.\nBecause the new study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\nAnother question is how reversible this would be in terms of restoring sperm counts, Alukal said.\nThat's apart from mild-to-moderate acne or an increase in acne, which was seen in about 21 percent of participants.\nThe results of the study, funded by the U.S. National Institutes of Child Health and Human Development, were presented at the recent Endocrine Society annual meeting, held in Houston.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "We\u2019re going to take a hard line on this criterion. The comments from the one independent source appear to be confined to potential for men using a contraceptive and not to the study or the results and their implications.\u00a0 So, while there is an independent source, the comments were not relevant to the study per se.\u00a0 SInce surrogate measures were sought as an outcome measure, the comments of an independent expert related to the study results would have been informative.", "answer": 0}, {"article": "This slowly progressive enlargement of the prostate can make urination difficult or painful and send men trudging to the bathroom many times during the day and night.\nSurprisingly, his case is not unique.\u201d\n\nMany doctors are now urging men to become proactive earlier to prevent chronic problems in the future.\nWatchful waiting, or monitoring symptoms while holding off on medical or surgical treatments, is a reasonable plan for these men, he added.\nNor does it lead to cancer.\nUrological experts are beginning to rethink treatments, too, based on symptoms and how much a man is bothered by them.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "Three urologists were quoted for this story.\u00a0 It would have been helpful to include the perspective of a clinician who would have made the point that postponing active treatment is a viable option. ", "answer": 1}, {"article": "46 babies had a brother or sister with known autism, which means they themselves are at an increased risk for the neurodevelopmental disorder that affects about one in 110 children according to the Centers for Disease Control and Prevention.\nHe, too, is hopeful that further research will provide more concrete information.\nBut she cautions that a lot more work needs to be done.\n\"The only thing slowing us down right now is funding.\"\nWiznitzer \u2013 a pediatric neurologist at Rainbow Babies & Children's Hospital in Cleveland, Ohio \u2013 notes that what the study can't tell us is what the differences in brain activity between the two groups of babies actually mean.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story made good use of outside experts, although we were dismayed to see the cliched \u201choly grail\u201d reference, so beloved by researchers and journalists.", "answer": 1}, {"article": "BRCA mutations cause about 5 to 10 percent of breast cancers and 10 to 15 percent of ovarian cancers among white women in the United States.\nHer mother, aunt and grandmother died of cancer.\nThey also said Ms. Jolie Pitt\u2019s decision to discuss her own choices so frankly will encourage women in similar situations to consider their own options.\nCancer experts said Tuesday that the actress and filmmaker Angelina Jolie Pitt was wise to have had her ovaries and fallopian tubes removed last week because she carries a genetic mutation, BRCA1, that significantly increases the risk of ovarian cancer, a disease so difficult to detect that it is often found only at an advanced, untreatable stage.\nIt is unclear how common the mutations are in other racial and ethnic groups.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story provides excellent comments from three experts in the field.\u00a0 No conflicts of interest are apparent.", "answer": 1}, {"article": "Asked if the 34% improvement in cognitive decline is meaningful to a patient, Carrillo said, \"I have a family member with AD.\nLarger studies in many more patients are needed before the drug will be available, though, she says.\nThe results really became clear when the researchers looked only at those patients with mild, early-stage disease.\nThere was even a hint that the drug helped to slow the decline in functioning.\nMaria Carrillo, PhD, a neuroscientist and vice president for medical and scientific relations for the Alzheimer\u2019s Association, calls the results \"encouraging\" and says she hopes development will continue.\n", "question": "Does the story use independent sources and identify conflicts of interest?", "explanation": "The story includes independent experts, although their independence from the drug maker\u2019s research is implied rather than clearly declared. AP, though, did a better job.", "answer": 1}]